{"gene":"FOXC2","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":1993,"finding":"MFH-1 (FOXC2) encodes a forkhead domain protein that binds the HNF3 binding site, acting as a DNA-binding transcription factor expressed in developing mesenchyme.","method":"Recombinant protein DNA-binding assay (HNF3 binding site); expression analysis in embryos","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct in vitro DNA-binding demonstrated with recombinant protein, single lab, single method","pmids":["8325367"],"is_preprint":false},{"year":1997,"finding":"FOXC2 (MFH-1) protein acts as a positive transactivator; both mouse and human MFH-1 proteins have transcriptional activation activity. The gene has no introns and mouse/human proteins share 94% amino acid identity.","method":"Transcriptional activity assay (transfection-based reporter); gene structure determination","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct transactivation assay, single lab, single method","pmids":["9169153"],"is_preprint":false},{"year":1997,"finding":"Loss of FOXC2 (MFH-1) in mice causes interrupted aortic arch and craniofacial/vertebral skeletal defects, establishing an essential role in neural-crest-derived aortic arch remodeling and skeletogenesis.","method":"Targeted gene knockout in mice; histological and anatomical phenotype analysis","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — constitutive knockout with defined developmental phenotype, replicated across multiple knockout studies","pmids":["9409679"],"is_preprint":false},{"year":2000,"finding":"Haploinsufficiency of FOXC2 (via nonsense and frameshift mutations) causes lymphedema-distichiasis syndrome in humans, establishing FOXC2 as a dosage-sensitive transcription factor required for lymphatic development.","method":"Human mutation analysis (sequencing of FOXC2 coding region in LD families); functional inference from loss-of-function mutations","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple independent families with inactivating mutations, replicated across many subsequent studies","pmids":["11078474"],"is_preprint":false},{"year":2000,"finding":"FOXC2 (MFH-1) is required for BMP-2-induced osteoblastic differentiation of C2C12 myoblasts; antisense suppression of MFH-1 reduced BMP-2-induced alkaline phosphatase activity and osteocalcin production.","method":"Antisense stable transfection in C2C12 cells; alkaline phosphatase assay; osteocalcin measurement","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — loss-of-function with defined cellular phenotype, single lab, single method","pmids":["10722840"],"is_preprint":false},{"year":2001,"finding":"Overexpression of FOXC2 in adipocytes increases sensitivity of the beta-adrenergic–cAMP–PKA signaling pathway by altering adipocyte PKA holoenzyme composition, leading to a lean and insulin-sensitive phenotype in transgenic mice.","method":"Transgenic mouse overexpression; biochemical PKA holoenzyme composition analysis; metabolic phenotyping","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — transgenic model with biochemical mechanism (PKA holoenzyme), multiple metabolic readouts, highly cited foundational study","pmids":["11551504"],"is_preprint":false},{"year":2001,"finding":"Foxc1 and Foxc2 have dose-dependent cooperative roles in somitogenesis; compound homozygous Foxc1;Foxc2 mutants show complete absence of segmented paraxial mesoderm and require both genes for transcription of paraxis, Mesp1, Mesp2, Hes5, and Notch1 in anterior presomitic mesoderm.","method":"Compound genetic knockout in mice; in situ hybridization for downstream target genes; genetic epistasis analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — compound mutant genetic epistasis with multiple molecular readouts, replicated across compound heterozygotes","pmids":["11562355"],"is_preprint":false},{"year":2001,"finding":"FOXC2 and FOXD1 specifically activate the 1b promoter of the PKA RIα subunit gene in adipocytes; FOXC2 acts by releasing a transcriptional repressor from an upstream region, and protein kinase B alpha/Akt1 cooperates to enhance this activation.","method":"Promoter deletion mapping; bandshift (EMSA) assays; co-transfection reporter assays in 3T3-L1 adipocytes and Sertoli cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — EMSA plus reporter assays with deletion mapping, two orthogonal methods, single lab","pmids":["11943768"],"is_preprint":false},{"year":2001,"finding":"BMP-2 and BMP-4/7 treatment of mesodermal progenitor C1 cells and limb mesenchyme upregulates Mfh1/Foxc2 expression; BMP-7 implantation in limb bud organ culture induces Mfh1 expression, placing FOXC2 downstream of BMP signaling in skeletal precursors.","method":"In vitro BMP treatment of cell lines; in situ hybridization; limb bud organ culture with BMP protein implantation","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vitro and ex vivo methods, single lab, consistent results across models","pmids":["11585339"],"is_preprint":false},{"year":2004,"finding":"FoxC2 blocks adipogenesis in 3T3-L1 preadipocytes by inhibiting PPARγ-mediated expression of a subset of adipogenic genes (C/EBPα, adiponectin, perilipin) without affecting PPARγ DNA binding or transactivation from a PPARγ response element.","method":"Overexpression in 3T3-L1 cells and Swiss fibroblasts; immunoblotting; PPARγ transactivation reporter assay; PPARγ DNA-binding assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — multiple cellular assays and reporter assays with mechanistic resolution, single lab","pmids":["15277530"],"is_preprint":false},{"year":2004,"finding":"Foxc1 and Foxc2 negatively regulate intermediate mesoderm formation and drive paraxial mesoderm cell fate specification; their misexpression in prospective intermediate mesoderm causes cells to acquire paraxial (somite) fate markers Pax7 and Paraxis.","method":"Mouse double knockout phenotyping; chick gain-of-function electroporation; in situ hybridization for lineage markers","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — complementary loss- and gain-of-function in two model systems with molecular readouts","pmids":["15196959"],"is_preprint":false},{"year":2007,"finding":"FOXC2 is induced downstream of EMT-triggering signals (TGF-β1, Snail, Twist, Goosecoid) and is required for metastasis of murine mammary carcinoma cells to the lung; overexpression of FOXC2 enhances metastatic ability.","method":"Gene expression profiling; shRNA knockdown; FOXC2 overexpression in mammary carcinoma cells; in vivo lung metastasis assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo loss- and gain-of-function with defined metastatic phenotype, multiple EMT inducers tested","pmids":["17537911"],"is_preprint":false},{"year":2008,"finding":"Foxc2 directly activates the Ang-2 (angiopoietin-2) promoter in adipocytes; transgenic overexpression of FOXC2 in adipose tissue causes altered vascular patterning that is almost completely reversed by an Ang-2-specific antagonist.","method":"Transgenic mouse model; promoter luciferase reporter assay (direct activation of Ang-2 promoter); pharmacological antagonist rescue","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct promoter activation assay combined with in vivo genetic and pharmacological rescue, multiple orthogonal methods","pmids":["18621714"],"is_preprint":false},{"year":2008,"finding":"Foxc2 directly regulates integrin beta3 (Itgb3) expression through multiple forkhead-binding elements within the Itgb3 promoter; Foxc2 overexpression enhances endothelial cell migration and adhesion, an effect blocked by Itgb3 neutralizing antibody, and promotes microvessel outgrowth in ex vivo aortic ring assay.","method":"Gene expression profiling; promoter reporter assay with forkhead-binding element mapping; Itgb3 neutralizing antibody; Foxc2 heterozygous mutant mouse endothelial cells; ex vivo aortic ring assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct promoter binding mapped, loss-of-function in primary cells, ex vivo functional assay, multiple orthogonal methods","pmids":["18579532"],"is_preprint":false},{"year":2010,"finding":"FOXC2 transcriptionally represses p120-catenin (CTNND1) in non-small cell lung cancer cells by directly binding the p120ctn promoter between positions +267 and +282, as shown by EMSA; FOXC2 knockdown increases p120ctn expression and E-cadherin levels.","method":"Luciferase reporter assay with serial promoter deletions; EMSA (electrophoretic mobility shift assay); RNAi knockdown; immunoblotting","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct DNA binding confirmed by EMSA, promoter deletion mapping, and loss-of-function rescue, multiple orthogonal methods","pmids":["20460685"],"is_preprint":false},{"year":2010,"finding":"In Xenopus, foxc2 functions in a transcriptional network for podocyte specification; combined knockdown of wt1 and foxc2 abolishes all podocyte marker gene expression, and co-expression of wt1 and foxc2 increases podocyte gene expression, with Notch signaling required for ectopic induction.","method":"Antisense morpholino knockdown in Xenopus; gain-of-function overexpression; in situ hybridization; genetic epistasis analysis","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic loss- and gain-of-function in multiple combinations with defined molecular readouts, two orthogonal approaches","pmids":["20431116"],"is_preprint":false},{"year":2012,"finding":"PROX1 and FOXC2 cooperate with shear stress/mechanotransduction to control expression of connexin37 and activation of calcineurin/NFAT signaling during lymphatic valve formation; connexin37 and calcineurin are required for valve territory assembly.","method":"In vitro shear stress assay on lymphatic endothelial cells; knockdown of PROX1 and FOXC2; analysis of connexin37 expression and calcineurin/NFAT signaling; mouse developmental genetics","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic pathway dissection combining cell-based shear stress assays with in vivo mouse genetics and molecular signaling readouts","pmids":["22306086"],"is_preprint":false},{"year":2013,"finding":"FOXC2 induces Wnt4 expression by directly interacting with the Wnt4 promoter region, leading to elevated BMP4 and RhoA-GTP, which inhibits myoblast fusion; sustained FOXC2 expression redirects myoblast commitment toward osteogenesis.","method":"Chromatin immunoprecipitation; promoter reporter assay; gain- and loss-of-function in C2C12 myoblasts; osteogenic differentiation assay","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — ChIP confirms direct promoter binding, overexpression/knockdown with defined phenotype, single lab","pmids":["23645207"],"is_preprint":false},{"year":2013,"finding":"FOXC2 expression confers cancer stem cell (CSC) properties and spontaneous metastasis; FOXC2 transcriptionally regulates PDGFR-β, and PDGFR inhibition with sunitinib reduces CSC and metastatic properties of FOXC2-expressing tumor cells.","method":"Lentiviral shRNA knockdown; FOXC2 overexpression; mammosphere-forming assay; tumor initiation assay; gene expression profiling; pharmacological inhibition","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays with loss- and gain-of-function, PDGFR-β identified as downstream target, single lab","pmids":["23378344"],"is_preprint":false},{"year":2013,"finding":"BSTA promotes mTORC2-mediated phosphorylation of Akt1 at Ser473, which suppresses FoxC2 expression to promote adipocyte differentiation; BSTA-Akt1 interaction is required for this mTORC2-BSTA-Akt1-FoxC2 signaling mechanism.","method":"Gene-trap murine embryonic stem cells; co-immunoprecipitation (BSTA-Akt1 complex); phosphorylation assays; FoxC2 expression analysis; adipocyte differentiation assay","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — co-IP of complex, phosphorylation assay, genetic loss-of-function, multiple orthogonal methods establishing pathway","pmids":["23300339"],"is_preprint":false},{"year":2013,"finding":"SENP3-mediated de-SUMOylation of FOXC2 enhances its transcriptional activity; FOXC2 is a substrate of the SUMO2/3-specific protease SENP3, and a SUMO-less FOXC2 transcriptionally activates N-cadherin expression to promote EMT in gastric cancer.","method":"Co-immunoprecipitation; SUMO substrate biochemical assay; SENP3 overexpression/knockdown; N-cadherin promoter reporter; cell migration assay; nude mouse xenograft","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — biochemical identification of FOXC2 as SENP3 substrate, co-IP, reporter assay, functional phenotype, multiple orthogonal methods","pmids":["25216525"],"is_preprint":false},{"year":2013,"finding":"FOXC2 phosphorylation on eight evolutionarily conserved proline-directed serine/threonine residues regulates its transcriptional activity in lymphatic endothelial cells; phosphorylation controls selective FOXC2 recruitment to chromatin, and a phosphorylation-deficient mutant fails to induce vascular remodeling in vivo.","method":"Genome-wide ChIP-seq (location analysis) in lymphatic endothelial cells; phospho-mutant FOXC2 constructs; in vivo vascular remodeling assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genome-wide chromatin occupancy analysis, site-directed mutagenesis, in vivo functional validation, multiple orthogonal methods","pmids":["23878394"],"is_preprint":false},{"year":2014,"finding":"FOXC2 directly binds the MET promoter to increase its transcriptional activity, activating the HGF-MET signaling pathway to promote colorectal cancer invasion and metastasis.","method":"Luciferase reporter assay; chromatin immunoprecipitation (ChIP); FOXC2 overexpression; MET inhibition rescue; orthotopic mouse metastasis model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct promoter binding confirmed by ChIP and luciferase, MET inhibition rescue, in vivo validation, multiple orthogonal methods","pmids":["25381815"],"is_preprint":false},{"year":2014,"finding":"Casein kinase 2 (CK2) associates with FOXC2 and phosphorylates it at serine 124, retaining FOXC2 in the cytoplasm of normal epithelial cells; CK2 inhibition or downregulation of CK2β causes nuclear accumulation of FOXC2 and mesenchymal gene expression.","method":"In vitro kinase assay (CK2 phosphorylation of FOXC2 at S124); co-immunoprecipitation (CK2-FOXC2 association); site-directed mutagenesis (S124L and S124D); CK2β knockdown; subcellular fractionation/immunofluorescence; cell migration assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay, co-IP, phospho-site mutagenesis with functional readout, subcellular localization experiments, multiple orthogonal methods","pmids":["25486430"],"is_preprint":false},{"year":2014,"finding":"FOXC2 directly binds the p120-catenin promoter and transcriptionally represses it, with PKCα acting upstream of FOXC2 in this signaling axis; loss of p120-catenin destabilizes E-cadherin at adherens junctions and promotes cell migration.","method":"Chromatin immunoprecipitation (ChIP); dual luciferase promoter assay; PKCα and FOXC2 knockdown; immunofluorescence of E-cadherin/p120-catenin localization; transwell migration/invasion assays","journal":"BMC cancer","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP confirms direct promoter binding, luciferase reporter, knockdown with cellular phenotype, multiple orthogonal methods, single lab","pmids":["29216867"],"is_preprint":false},{"year":2015,"finding":"FOXC2 inactivation in lymphatic endothelial cells causes abnormal shear stress sensing, promotes junction disassembly and cell cycle entry; loss of FOXC2-dependent quiescence is mediated by the Hippo pathway transcriptional coactivator TAZ, leading to cell death and vascular lumen collapse.","method":"Inducible endothelial-specific Foxc2 deletion in mice; in vitro shear stress assay; TAZ pathway analysis; cell junction and cytoskeleton imaging; cell cycle analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible conditional knockout with defined molecular mechanism (TAZ), in vitro and in vivo orthogonal approaches","pmids":["26389677"],"is_preprint":false},{"year":2015,"finding":"FOXC2 and FOXC1 regulate ERK signaling in lymphatic vessel growth; LEC-specific deletion of Foxc1, Foxc2, or both results in increased LEC proliferation and aberrant expression of Ras regulators leading to ERK hyperactivation; pharmacological ERK inhibition rescues the enlarged lymphatic vessel phenotype.","method":"LEC-specific conditional knockout in mice; embryonic phenotyping; ERK activation assays; pharmacological ERK inhibition in utero","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional knockout with defined molecular pathway, pharmacological rescue, multiple genetic combinations tested","pmids":["27214551"],"is_preprint":false},{"year":2015,"finding":"FOXF2 directly targets the FOXC2 promoter to negatively regulate FOXC2 transcription in basal-like breast cancer cells; FOXC2 mediates FOXF2-regulated EMT phenotype and multidrug resistance.","method":"Promoter reporter assay; FOXF2 overexpression/knockdown with FOXC2 expression readout; EMT and drug resistance phenotyping","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter assay plus functional rescue experiments, single lab, two orthogonal methods","pmids":["26210254"],"is_preprint":false},{"year":2015,"finding":"p38MAPK signaling promotes FOXC2 expression in prostate cancer; inhibition of p38 using a p38 inhibitor reduces FOXC2 levels, restores epithelial attributes and androgen deprivation therapy sensitivity, and reduces circulating tumor cells in vivo.","method":"p38 inhibitor treatment; FOXC2 expression analysis; in vivo tumor model with drug treatment; flow cytometry for circulating tumor cells","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway placement with in vivo functional readout, single lab","pmids":["26804168"],"is_preprint":false},{"year":2015,"finding":"Foxc2 and Connexin37 function in a common developmental pathway for lymphatic valve formation; Foxc2(+/-); Cx37(-/-) compound mutant mice display severe lymphatic defects not seen in single mutants, including absence of lymphatic valves.","method":"Compound genetic knockout in mice (Foxc2+/-;Cx37-/-); lymphatic vascular phenotyping; quantitative morphometry","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis via compound mutant showing synthetic lethality/phenotype, rigorous quantitative documentation","pmids":["26079578"],"is_preprint":false},{"year":2015,"finding":"Notch signaling acts upstream of Foxc2 in hemogenic endothelial cells to promote definitive hematopoiesis; Foxc2 is a highly upregulated Notch target in hemogenic endothelium, and loss of Foxc2 orthologs in zebrafish and mice impairs definitive hematopoiesis.","method":"Mouse embryonic stem cell differentiation with Notch induction; zebrafish morpholino knockdown; mouse embryo analysis; transcriptional profiling identifying Foxc2 as Notch target","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis established in two model organisms (mouse and zebrafish) with defined pathway placement","pmids":["25587036"],"is_preprint":false},{"year":2016,"finding":"FOXC2 disease-causing mutations outside the forkhead domain cause either loss or gain of transactivation activity at FOXC1/FOXC2 response elements; a frameshift mutant protein is sequestered in nuclear aggregates while all mutants retain nuclear localization.","method":"Subcellular localization (immunofluorescence); transactivation reporter assay on FOXC1/FOXC2 response elements; analysis of six patient-derived mutations","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay and localization studies with six independent mutations, two orthogonal methods, single lab","pmids":["27276711"],"is_preprint":false},{"year":2016,"finding":"FOXC1 and FOXC2 differentially regulate cytoskeletal activity in lymphatic valves: FOXC1 knockdown increases focal adhesions and actin stress fibers, while FOXC2 knockdown increases focal adherens and disrupts cell junctions via increased ROCK activation; ROCK inhibition rescues these defects.","method":"siRNA knockdown of FOXC1 and FOXC2 in human lymphatic endothelial cells; inducible endothelial-specific deletion in mice; ROCK inhibitor treatment; cytoskeletal imaging; valve phenotyping","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro mechanistic dissection with pharmacological rescue, validated in vivo, multiple orthogonal methods","pmids":["32510325"],"is_preprint":false},{"year":2016,"finding":"TLR4 signaling induces ERK phosphorylation, which leads to FOXC2-ERK protein interaction, ERK-dependent phosphorylation of FOXC2 on serine/threonine residues, and subsequent FOXC2 binding to the DLL4 promoter to activate DLL4 transcription and inflammatory angiogenesis.","method":"Co-immunoprecipitation (FOXC2-ERK); ChIP (FOXC2 binding to DLL4 promoter); ERK dominant-negative transfection; FOXC2-siRNA; pharmacological ERK inhibition; in vivo LPS mouse model","journal":"The Journal of physiology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — co-IP, ChIP, mutagenesis, and in vivo genetic/pharmacological approaches, multiple orthogonal methods","pmids":["29380370"],"is_preprint":false},{"year":2017,"finding":"FOXC2 interacts with YAP and TEAD to activate YAP signaling, and this FOXC2-YAP pathway positively regulates expression of Hexokinase 2 (HK2) to promote glycolysis in nasopharyngeal carcinoma cells.","method":"Co-immunoprecipitation (FOXC2 with YAP and TEAD); HK2 expression analysis; FOXC2/YAP knockdown; metabolic (glycolysis) assay; in vivo xenograft","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP establishes protein-protein interaction, functional readout with glycolysis assay, single lab","pmids":["28433696"],"is_preprint":false},{"year":2017,"finding":"Foxc2 inhibits LPS-induced inflammation in white adipose tissue via the leptin-JAK2/STAT3 pathway; STAT3 physically interacts with PRDM16 to form a complex that promotes WAT browning; Foxc2 overexpression ameliorates inflammation and promotes adipose browning in obese mice.","method":"Co-immunoprecipitation (STAT3-PRDM16 complex); ChIP (Foxc2 binding to CREB/leptin promoter region); Foxc2 overexpression in vivo; LPS-induced inflammatory model","journal":"International journal of obesity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP of STAT3-PRDM16 complex and ChIP, in vivo overexpression model, single lab","pmids":["28925407"],"is_preprint":false},{"year":2019,"finding":"Crystal structures of the FOXC2 DNA-binding domain (DBD) in complex with DNA revealed that helix H3 makes all base-specific contacts, while the N-terminus, wing 1, and C-terminus make additional phosphate contacts; structural and biochemical analyses revised the previously proposed DNA recognition mechanism.","method":"X-ray crystallography (two crystal structures with different DNA sites); biochemical DNA-binding assays; bioinformatics analysis of disease mutations","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with functional biochemical validation and mechanistic interpretation, rigorous structural biology","pmids":["30722065"],"is_preprint":false},{"year":2019,"finding":"Foxc2 overexpression in BMSCs promotes osteogenesis and represses adipogenesis via activation of canonical Wnt-β-catenin signaling; XAV939 (Wnt-β-catenin pathway inhibitor) suppresses Foxc2-mediated differentiation.","method":"Lentiviral Foxc2 overexpression in rabbit BMSCs; osteogenic/adipogenic differentiation assays; β-catenin/TCF-LEF reporter assay; pharmacological inhibitor (XAV939)","journal":"Molecular and cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — overexpression with pharmacological pathway validation and reporter assay, single lab","pmids":["24122419"],"is_preprint":false},{"year":2019,"finding":"H19 lncRNA binds to Foxc2 protein (RNA-protein interaction); H19/Foxc2 synergistically regulate Wnt4 promoter expression; Foxc2 binds to the Wnt4 promoter and promotes its transcription to drive BMSC osteogenic differentiation via Wnt-β-catenin pathway.","method":"RNA immunoprecipitation; RNA pull-down; ChIP (Foxc2 binding to Wnt4 promoter); overexpression/knockdown; osteogenic differentiation assays","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — ChIP plus RIP/pull-down for protein-RNA interaction, multiple orthogonal methods, single lab","pmids":["30633332"],"is_preprint":false},{"year":2020,"finding":"FOXC2 disease mutations cause loss or gain of transactivation function and some mutant proteins are sequestered into nuclear aggregates causing cell death, providing molecular basis for lymphedema distichiasis pathogenesis.","method":"Subcellular localization (immunofluorescence); transactivation reporter assay; cell viability assay; analysis of nine patient-derived mutations","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay and localization/viability assays across multiple mutations, two orthogonal methods, single lab","pmids":["32698337"],"is_preprint":false},{"year":2021,"finding":"Foxc2 inactivation in adult lymphatic endothelium compromises gut epithelial barrier, promotes dysbiosis and bacterial translocation, increases angiopoietin-2, and skews lymphatic endothelial subset specialization toward pro-fibrotic identities; commensal microbiota depletion rescues systemic inflammation and improves survival.","method":"Inducible adult-specific Foxc2 deletion in mice; single-cell atlas of lymphatic endothelial subtypes; microbiome analysis; microbiota depletion rescue experiment","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible conditional knockout with single-cell resolution, microbiota rescue validation, defined mechanistic pathway","pmids":["34272244"],"is_preprint":false},{"year":2022,"finding":"CircKIF18A (exosomal circRNA) binds to FOXC2 protein in brain endothelial cells, stabilizes FOXC2 and promotes its nuclear translocation; nuclear FOXC2 directly binds promoters of ITGB3, CXCR4, and DLL4 to upregulate their expression and activate PI3K/AKT signaling to promote glioblastoma angiogenesis.","method":"Co-immunoprecipitation (circKIF18A-FOXC2 RNA-protein interaction); ChIP (FOXC2 binding to ITGB3, CXCR4, DLL4 promoters); promoter reporter assays; gain/loss-of-function; in vivo tumorigenicity","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — ChIP confirms direct promoter binding, co-IP for protein-RNA interaction, functional in vivo validation, single lab","pmids":["35637250"],"is_preprint":false},{"year":2023,"finding":"FOXC1 and FOXC2 in blood and lymphatic endothelial cells directly bind regulatory elements of CXCL12 and RSPO3 loci, respectively; loss of endothelial Foxc2 impairs RSPO3 expression in LECs, reducing Wnt signaling in intestinal stem cells and worsening ischemia-reperfusion injury; RSPO3 treatment rescues the damage.","method":"EC- and LEC-specific conditional Foxc2 knockout mice; ChIP (FOXC2 binding to CXCL12 and RSPO3 regulatory elements); rescue with recombinant CXCL12 and RSPO3; intestinal stem cell Wnt signaling assay","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP confirms direct binding, conditional genetic knockout in cell-type specific manner, ligand rescue validation, multiple orthogonal methods","pmids":["37154714"],"is_preprint":false},{"year":2023,"finding":"FOXC2 promotes vasculogenic mimicry (VM) in solid tumors by driving ectopic expression of endothelial genes in tumor cells; this process is stimulated by hypoxia and VM-proficient tumors are resistant to anti-angiogenic therapy; suppression of Foxc2 augments anti-angiogenic response.","method":"FOXC2 overexpression/knockdown in diverse tumor cell lines; VM channel formation assay; hypoxia treatment; anti-angiogenic therapy combination in vivo","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss- and gain-of-function across multiple tumor types with defined VM phenotype and therapeutic readout, single lab","pmids":["37499655"],"is_preprint":false},{"year":2016,"finding":"FOXC2 regulates G2/M cell cycle transition in cancer stem cell-enriched breast cancer cells; FOXC2 protein levels accumulate in G2 and decrease during mitosis; PLK1 activity is required for FOXC2 protein stability, and PLK1 inhibition reduces FOXC2 protein levels and sensitizes FOXC2-expressing CSC-enriched cells to PLK1 inhibitors.","method":"Cell cycle synchronization; FOXC2 protein level quantification at cell cycle stages; FOXC2 knockdown with cell cycle analysis; PLK1 inhibitor treatment; flow cytometry","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell cycle-resolved protein level measurement, pharmacological PLK1 inhibition, loss-of-function, single lab","pmids":["27064522"],"is_preprint":false}],"current_model":"FOXC2 is a forkhead/winged-helix transcription factor that binds DNA through its helix H3-containing DBD (crystal structure resolved), activates or represses target gene promoters (MET, ITGB3, DLL4, Ang-2, Wnt4, p120-catenin, CXCL12, RSPO3, PKA RIα) through direct promoter occupancy, and is regulated post-translationally by CK2-mediated phosphorylation at Ser124 (controlling cytoplasmic vs. nuclear localization), by proline-directed phosphorylation (controlling chromatin recruitment), and by SENP3-mediated de-SUMOylation (enhancing transcriptional activity); it functions downstream of Notch, BMP, TGF-β, ERK/TLR4, and mTORC2-Akt signaling to control lymphatic valve formation and maintenance (via connexin37/calcineurin-NFAT and ROCK/cytoskeletal pathways), arterial specification, hematopoiesis, adipocyte metabolism (through PKA holoenzyme composition), osteogenesis (via Wnt-β-catenin), and EMT/metastasis (by inducing mesenchymal gene programs and cancer stem cell properties)."},"narrative":{"mechanistic_narrative":"FOXC2 is a forkhead/winged-helix transcription factor that binds DNA through its forkhead domain and acts predominantly as a transcriptional activator across mesenchymal, endothelial, and metabolic programs [PMID:8325367, PMID:9169153, PMID:30722065]. Crystal structures of its DNA-binding domain in complex with DNA establish that helix H3 makes all base-specific contacts while the N-terminus, wing 1, and C-terminus contribute phosphate contacts [PMID:30722065]. In development, FOXC2 acts cooperatively with the paralog FOXC1 to specify paraxial mesoderm and drive somitogenesis through targets including paraxis, Mesp1/2, Hes5, and Notch1 [PMID:11562355, PMID:15196959], and its loss causes interrupted aortic arch and skeletal defects in mice [PMID:9409679]. In humans, FOXC2 haploinsufficiency causes lymphedema-distichiasis syndrome, defining it as a dosage-sensitive regulator of lymphatic development [PMID:11078474], and disease mutations alter transactivation or sequester the protein into nuclear aggregates [PMID:27276711, PMID:32698337]. FOXC2 is a central regulator of lymphatic valve formation and endothelial quiescence, operating through PROX1/connexin37/calcineurin-NFAT signaling under shear stress [PMID:22306086, PMID:26079578], through ROCK/cytoskeletal control of cell junctions [PMID:32510325], and through restraint of TAZ-driven cell cycle entry and ERK hyperactivation [PMID:26389677, PMID:27214551]. It functions downstream of Notch in hemogenic endothelium to support definitive hematopoiesis [PMID:25587036] and downstream of BMP signaling to promote osteoblastic differentiation [PMID:10722840, PMID:11585339] via Wnt-β-catenin and Wnt4 induction [PMID:24122419, PMID:30633332, PMID:23645207]. In adipocytes FOXC2 reprograms β-adrenergic/cAMP/PKA signaling by altering PKA holoenzyme composition to produce a lean, insulin-sensitive phenotype [PMID:11551504], directly activating the PKA RIα 1b promoter [PMID:11943768] and blocking PPARγ-dependent adipogenesis [PMID:15277530]. In cancer FOXC2 is induced by EMT-triggering signals and drives metastasis, cancer stem cell properties, and mesenchymal gene programs by directly occupying target promoters—activating MET, ITGB3, DLL4, and N-cadherin, and repressing p120-catenin [PMID:17537911, PMID:20460685, PMID:25381815, PMID:25216525, PMID:29216867]. FOXC2 activity is tuned post-translationally by CK2 phosphorylation at Ser124 (controlling cytoplasmic versus nuclear localization) [PMID:25486430], proline-directed phosphorylation that governs chromatin recruitment [PMID:23878394], ERK-dependent phosphorylation linking TLR4 signaling to DLL4 activation [PMID:29380370], and SENP3-mediated de-SUMOylation that enhances its transcriptional output [PMID:25216525].","teleology":[{"year":1993,"claim":"Established the foundational molecular identity of FOXC2 as a sequence-specific DNA-binding forkhead protein, answering what class of factor it is.","evidence":"Recombinant protein DNA-binding to the HNF3 site and embryonic expression analysis","pmids":["8325367"],"confidence":"Medium","gaps":["No in vivo targets identified","Transactivation versus repression not resolved"]},{"year":1997,"claim":"Defined FOXC2 as a positive transactivator with high mouse/human conservation, framing it as a functional transcription factor rather than merely a DNA binder.","evidence":"Transfection-based reporter assays and gene structure determination","pmids":["9169153"],"confidence":"Medium","gaps":["No endogenous promoter targets defined","Regulatory inputs unknown"]},{"year":1997,"claim":"Demonstrated an essential developmental role by showing knockout causes aortic arch and skeletal defects, placing FOXC2 in neural-crest-derived remodeling.","evidence":"Constitutive mouse knockout with histological/anatomical phenotyping","pmids":["9409679"],"confidence":"High","gaps":["Direct target genes mediating the phenotype not identified","Cell-autonomy not resolved"]},{"year":2000,"claim":"Linked FOXC2 to human disease, establishing it as a dosage-sensitive transcription factor required for lymphatic development.","evidence":"Mutation sequencing in lymphedema-distichiasis families","pmids":["11078474"],"confidence":"High","gaps":["Lymphatic target genes not yet defined","Mechanism of dosage sensitivity unresolved"]},{"year":2000,"claim":"Positioned FOXC2 downstream of BMP signaling in skeletal differentiation, answering how it contributes to osteogenesis.","evidence":"Antisense suppression in C2C12 with osteoblast marker readouts; BMP treatment and limb bud organ culture","pmids":["10722840","11585339"],"confidence":"Medium","gaps":["Direct osteogenic target promoters not mapped","Single lineage model"]},{"year":2001,"claim":"Revealed FOXC2 as a metabolic regulator that reprograms β-adrenergic/PKA signaling, explaining its lean/insulin-sensitive phenotype and identifying a direct promoter target.","evidence":"Transgenic overexpression with PKA holoenzyme biochemistry; PKA RIα 1b promoter mapping and EMSA","pmids":["11551504","11943768"],"confidence":"High","gaps":["Identity of the released repressor not defined","Physiological signal controlling FOXC2 in adipose unknown"]},{"year":2001,"claim":"Established cooperative, dose-dependent FOXC1/FOXC2 control of paraxial mesoderm specification and somitogenesis, defining downstream transcriptional targets.","evidence":"Compound mouse mutants and chick gain-of-function with in situ readouts for paraxis, Mesp1/2, Hes5, Notch1, Pax7","pmids":["11562355","15196959"],"confidence":"High","gaps":["Direct versus indirect target regulation not distinguished","Functional redundancy mechanism unresolved"]},{"year":2004,"claim":"Defined how FOXC2 blocks adipogenesis, showing it inhibits PPARγ-dependent gene expression without affecting PPARγ binding.","evidence":"Overexpression in 3T3-L1 with PPARγ transactivation and DNA-binding assays","pmids":["15277530"],"confidence":"Medium","gaps":["Mechanism of selective PPARγ target inhibition unknown","Direct DNA binding not shown"]},{"year":2007,"claim":"Connected FOXC2 to EMT and metastasis, establishing it as an effector induced by multiple EMT triggers and required for metastatic dissemination.","evidence":"Expression profiling, shRNA knockdown, overexpression, and in vivo lung metastasis assay","pmids":["17537911"],"confidence":"High","gaps":["Direct mesenchymal targets not yet identified","Mechanism of metastatic enhancement unresolved"]},{"year":2008,"claim":"Identified the first direct vascular and adhesion target genes (Ang-2, Itgb3) of FOXC2 with functional rescue, explaining its angiogenic activity.","evidence":"Transgenic models, promoter reporter/forkhead-element mapping, antagonist/neutralizing-antibody rescue, ex vivo aortic ring assay","pmids":["18621714","18579532"],"confidence":"High","gaps":["Full target repertoire not defined","Upstream signals controlling these targets in vivo unclear"]},{"year":2010,"claim":"Showed FOXC2 directly represses p120-catenin and operates within a podocyte specification network, broadening its repressor function and developmental scope.","evidence":"Promoter deletion/EMSA with RNAi in lung cancer cells; morpholino and gain-of-function epistasis in Xenopus","pmids":["20460685","20431116"],"confidence":"High","gaps":["Determinants of activation versus repression not defined","Cofactors at repressed promoters unknown"]},{"year":2012,"claim":"Defined the FOXC2 lymphatic valve mechanism, linking it with PROX1, shear stress, connexin37, and calcineurin/NFAT signaling.","evidence":"Shear stress assays on LECs with PROX1/FOXC2 knockdown and mouse developmental genetics","pmids":["22306086"],"confidence":"High","gaps":["Direct FOXC2 targets in valve program incompletely mapped","Mechanotransduction-to-FOXC2 link not molecular"]},{"year":2013,"claim":"Established post-translational control of FOXC2 chromatin recruitment by proline-directed phosphorylation, and de-SUMOylation by SENP3 as an activity switch.","evidence":"Genome-wide ChIP-seq with phospho-mutants and in vivo remodeling assay; SENP3 substrate biochemistry with N-cadherin reporter and xenograft","pmids":["23878394","25216525"],"confidence":"High","gaps":["Kinases responsible for the eight sites not all identified","How modifications direct site selection unresolved"]},{"year":2013,"claim":"Placed FOXC2 within mTORC2-Akt and Wnt signaling axes and expanded its cancer stem cell and osteogenic roles via PDGFR-β and Wnt4.","evidence":"Gene-trap ESCs with BSTA-Akt1 co-IP; ChIP/reporter for Wnt4 and PDGFR-β with differentiation and CSC assays","pmids":["23300339","23645207","23378344"],"confidence":"High","gaps":["Direct versus indirect PDGFR-β regulation not fully resolved","Integration of signaling inputs unclear"]},{"year":2014,"claim":"Resolved subcellular localization control by CK2 phosphorylation at Ser124 and identified MET as a direct target, mechanistically connecting FOXC2 to invasion.","evidence":"In vitro kinase assay, co-IP, S124 mutagenesis, fractionation; ChIP/luciferase for MET with metastasis model and PKCα-FOXC2-p120ctn axis","pmids":["25486430","25381815","29216867"],"confidence":"High","gaps":["Phosphatase opposing CK2 not identified","Crosstalk between CK2 and proline-directed phosphorylation unknown"]},{"year":2015,"claim":"Defined FOXC2 as a maintenance factor for lymphatic endothelial quiescence, acting through TAZ/Hippo and ERK to restrain proliferation and preserve junctions.","evidence":"Inducible endothelial Foxc2 deletion with TAZ pathway analysis and ERK activation/inhibition; Cx37 compound mutants","pmids":["26389677","27214551","26079578"],"confidence":"High","gaps":["Direct FOXC2 targets controlling TAZ/ERK not defined","Quiescence versus differentiation roles not fully separated"]},{"year":2015,"claim":"Situated FOXC2 within upstream regulatory circuits in cancer (FOXF2 repression, p38MAPK induction), explaining context-dependent FOXC2 levels and EMT/therapy resistance.","evidence":"Promoter reporter and overexpression/knockdown with EMT/drug-resistance phenotyping; p38 inhibitor in vivo","pmids":["26210254","26804168"],"confidence":"Medium","gaps":["Direct versus indirect regulation by p38 unresolved","Single tumor-type models"]},{"year":2016,"claim":"Detailed cytoskeletal and cell-cycle control by FOXC2, including ROCK-dependent junction regulation and PLK1-dependent protein stability.","evidence":"siRNA/inducible deletion with ROCK inhibitor rescue and cytoskeletal imaging; cell-cycle-resolved protein quantification with PLK1 inhibition","pmids":["32510325","27064522"],"confidence":"High","gaps":["Mechanism of PLK1-dependent stabilization not defined","Transcriptional targets driving cytoskeletal effects unmapped"]},{"year":2016,"claim":"Provided molecular basis for lymphedema-distichiasis by showing disease mutations alter transactivation and can form lethal nuclear aggregates.","evidence":"Patient-derived mutation panels with reporter, localization, and viability assays","pmids":["27276711","32698337"],"confidence":"Medium","gaps":["Genotype-phenotype correlation incomplete","Aggregate clearance pathway unknown"]},{"year":2017,"claim":"Identified FOXC2 protein-protein partnerships with YAP/TEAD and roles in metabolic reprogramming and adipose inflammation, expanding its interactome.","evidence":"Co-IP of FOXC2 with YAP/TEAD and glycolysis assays; STAT3-PRDM16 complex and leptin/JAK2-STAT3 axis with browning model","pmids":["28433696","28925407"],"confidence":"Medium","gaps":["Direct DNA targets of FOXC2-YAP complex not mapped","Single-lab interaction data"]},{"year":2019,"claim":"Resolved the FOXC2 DNA-recognition mechanism at atomic resolution and connected its osteogenic Wnt4 program to lncRNA H19 binding.","evidence":"Two crystal structures of the DBD-DNA complex with biochemistry; RIP/pull-down and ChIP for H19/Foxc2/Wnt4 with Wnt-β-catenin reporter","pmids":["30722065","24122419","30633332"],"confidence":"High","gaps":["Structural basis for cofactor selectivity not addressed","Functional role of H19-FOXC2 binding in vivo unclear"]},{"year":2021,"claim":"Extended FOXC2 function to adult lymphatic homeostasis, gut barrier integrity, and LEC subtype identity using single-cell resolution.","evidence":"Inducible adult Foxc2 deletion with single-cell atlas and microbiota-depletion rescue","pmids":["34272244"],"confidence":"High","gaps":["Direct targets defining LEC subtype identity not identified","Mechanism linking FOXC2 loss to barrier defect unresolved"]},{"year":2022,"claim":"Established RNA-mediated regulation of FOXC2 stability/localization and a coherent set of angiogenic promoter targets in tumor endothelium.","evidence":"circKIF18A-FOXC2 co-IP and ChIP on ITGB3/CXCR4/DLL4 promoters with PI3K/AKT readout and in vivo tumorigenicity","pmids":["35637250"],"confidence":"Medium","gaps":["Mechanism of circRNA-mediated stabilization not detailed","Single-lab data"]},{"year":2023,"claim":"Defined cell-type-specific FOXC1/FOXC2 target loci (CXCL12, RSPO3) regulating intestinal stem cell Wnt signaling, and a FOXC2-driven vasculogenic mimicry program conferring anti-angiogenic resistance.","evidence":"EC/LEC-specific knockouts with ChIP on CXCL12/RSPO3 and ligand rescue; VM channel assays under hypoxia with anti-angiogenic combination in vivo","pmids":["37154714","37499655"],"confidence":"High","gaps":["Full endothelial target network not defined","Determinants of FOXC1 versus FOXC2 target selectivity unresolved"]},{"year":null,"claim":"It remains unresolved how the combinatorial code of FOXC2 post-translational modifications and partner proteins selects context-specific target genes and the activation-versus-repression decision across its many tissue programs.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking phosphorylation/SUMOylation state to genome-wide site selection","Cofactor determinants of activation versus repression not defined","Tissue-specific target hierarchies incompletely mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,12,13,14,22,20,36]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,14,36]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[38,41]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[23,31,21,41]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[23]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,12,13,22,14]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,6,10,16,30]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[19,33,34,37,26]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,31,39,11,22]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[5,7,9,35,34]}],"complexes":[],"partners":["FOXC1","ERK","CK2","SENP3","YAP","TEAD","PROX1","AKT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q99958","full_name":"Forkhead box protein C2","aliases":["Forkhead-related protein FKHL14","Mesenchyme fork head protein 1","MFH-1 protein","Transcription factor FKH-14"],"length_aa":501,"mass_kda":53.7,"function":"Transcriptional activator","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q99958/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FOXC2","classification":"Not Classified","n_dependent_lines":57,"n_total_lines":1208,"dependency_fraction":0.04718543046357616},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FOXC2","total_profiled":1310},"omim":[{"mim_id":"609218","title":"FOVEAL HYPOPLASIA 2; FVH2","url":"https://www.omim.org/entry/609218"},{"mim_id":"608748","title":"BONE MORPHOGENETIC PROTEIN 10; BMP10","url":"https://www.omim.org/entry/608748"},{"mim_id":"605597","title":"FORKHEAD TRANSCRIPTION FACTOR FOXL2; FOXL2","url":"https://www.omim.org/entry/605597"},{"mim_id":"605120","title":"GROWTH/DIFFERENTIATION FACTOR 2; GDF2","url":"https://www.omim.org/entry/605120"},{"mim_id":"603252","title":"FORKHEAD BOX L1; FOXL1","url":"https://www.omim.org/entry/603252"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear bodies","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":37.0}],"url":"https://www.proteinatlas.org/search/FOXC2"},"hgnc":{"alias_symbol":["MFH-1"],"prev_symbol":["FKHL14"]},"alphafold":{"accession":"Q99958","domains":[{"cath_id":"1.10.10.10","chopping":"75-158","consensus_level":"high","plddt":93.6048,"start":75,"end":158}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99958","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99958-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99958-F1-predicted_aligned_error_v6.png","plddt_mean":55.16},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FOXC2","jax_strain_url":"https://www.jax.org/strain/search?query=FOXC2"},"sequence":{"accession":"Q99958","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99958.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99958/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99958"}},"corpus_meta":[{"pmid":"17537911","id":"PMC_17537911","title":"Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17537911","citation_count":489,"is_preprint":false},{"pmid":"11078474","id":"PMC_11078474","title":"Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome.","date":"2000","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11078474","citation_count":456,"is_preprint":false},{"pmid":"11551504","id":"PMC_11551504","title":"FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resistance.","date":"2001","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/11551504","citation_count":439,"is_preprint":false},{"pmid":"22306086","id":"PMC_22306086","title":"Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation.","date":"2012","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/22306086","citation_count":337,"is_preprint":false},{"pmid":"11562355","id":"PMC_11562355","title":"The murine winged helix transcription factors, Foxc1 and Foxc2, are both required for cardiovascular development and somitogenesis.","date":"2001","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/11562355","citation_count":294,"is_preprint":false},{"pmid":"23378344","id":"PMC_23378344","title":"FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23378344","citation_count":235,"is_preprint":false},{"pmid":"26389677","id":"PMC_26389677","title":"FOXC2 and fluid shear stress stabilize postnatal lymphatic vasculature.","date":"2015","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26389677","citation_count":207,"is_preprint":false},{"pmid":"9409679","id":"PMC_9409679","title":"Essential roles of the winged helix transcription factor MFH-1 in aortic arch patterning and skeletogenesis.","date":"1997","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9409679","citation_count":207,"is_preprint":false},{"pmid":"28323030","id":"PMC_28323030","title":"Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28323030","citation_count":171,"is_preprint":false},{"pmid":"14569043","id":"PMC_14569043","title":"Reduced expression of FOXC2 and brown adipogenic genes in human subjects with insulin resistance.","date":"2003","source":"Obesity research","url":"https://pubmed.ncbi.nlm.nih.gov/14569043","citation_count":119,"is_preprint":false},{"pmid":"18621714","id":"PMC_18621714","title":"FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodeling, and functions in adipose tissue.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18621714","citation_count":94,"is_preprint":false},{"pmid":"8325367","id":"PMC_8325367","title":"MFH-1, a new member of the fork head domain family, is expressed in developing mesenchyme.","date":"1993","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8325367","citation_count":90,"is_preprint":false},{"pmid":"15196959","id":"PMC_15196959","title":"The forkhead genes, Foxc1 and Foxc2, regulate paraxial versus intermediate mesoderm cell fate.","date":"2004","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/15196959","citation_count":87,"is_preprint":false},{"pmid":"8674414","id":"PMC_8674414","title":"Clustered arrangement of winged helix genes fkh-6 and MFH-1: possible implications for mesoderm development.","date":"1996","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/8674414","citation_count":84,"is_preprint":false},{"pmid":"15465483","id":"PMC_15465483","title":"Foxc2 is expressed in developing lymphatic vessels and other tissues associated with lymphedema-distichiasis syndrome.","date":"2004","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/15465483","citation_count":79,"is_preprint":false},{"pmid":"35392966","id":"PMC_35392966","title":"Stanniocalcin 1 promotes metastasis, lipid metabolism and cisplatin chemoresistance via the FOXC2/ITGB6 signaling axis in ovarian cancer.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35392966","citation_count":78,"is_preprint":false},{"pmid":"34272244","id":"PMC_34272244","title":"FOXC2 controls adult lymphatic endothelial specialization, function, and gut lymphatic barrier preventing multiorgan failure.","date":"2021","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/34272244","citation_count":76,"is_preprint":false},{"pmid":"26210254","id":"PMC_26210254","title":"FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.","date":"2015","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/26210254","citation_count":76,"is_preprint":false},{"pmid":"25896630","id":"PMC_25896630","title":"FOXC2 promotes chemoresistance in nasopharyngeal carcinomas via induction of epithelial mesenchymal transition.","date":"2015","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/25896630","citation_count":74,"is_preprint":false},{"pmid":"18579532","id":"PMC_18579532","title":"The Foxc2 transcription factor regulates angiogenesis via induction of integrin beta3 expression.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18579532","citation_count":73,"is_preprint":false},{"pmid":"26804168","id":"PMC_26804168","title":"Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26804168","citation_count":73,"is_preprint":false},{"pmid":"19185813","id":"PMC_19185813","title":"Foxc2 transcription factor: a newly described regulator of angiogenesis.","date":"2008","source":"Trends in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19185813","citation_count":70,"is_preprint":false},{"pmid":"25381815","id":"PMC_25381815","title":"FOXC2 promotes colorectal cancer metastasis by directly targeting MET.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25381815","citation_count":70,"is_preprint":false},{"pmid":"27214551","id":"PMC_27214551","title":"Foxc1 and Foxc2 deletion causes abnormal lymphangiogenesis and correlates with ERK hyperactivation.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27214551","citation_count":66,"is_preprint":false},{"pmid":"15277530","id":"PMC_15277530","title":"The forkhead transcription factor FoxC2 inhibits white adipocyte differentiation.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15277530","citation_count":65,"is_preprint":false},{"pmid":"20060810","id":"PMC_20060810","title":"The Foxc2 transcription factor regulates tumor angiogenesis.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20060810","citation_count":60,"is_preprint":false},{"pmid":"25069037","id":"PMC_25069037","title":"FOXC2 promotes colorectal cancer proliferation through inhibition of FOXO3a and activation of MAPK and AKT signaling pathways.","date":"2014","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/25069037","citation_count":59,"is_preprint":false},{"pmid":"24647631","id":"PMC_24647631","title":"Prox1 and FOXC2 act as regulators of lymphangiogenesis and angiogenesis in oral squamous cell carcinoma.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24647631","citation_count":58,"is_preprint":false},{"pmid":"25216525","id":"PMC_25216525","title":"De-SUMOylation of FOXC2 by SENP3 promotes the epithelial-mesenchymal transition in gastric cancer cells.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25216525","citation_count":56,"is_preprint":false},{"pmid":"20429416","id":"PMC_20429416","title":"The cooperative roles of Foxc1 and Foxc2 in cardiovascular development.","date":"2009","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/20429416","citation_count":55,"is_preprint":false},{"pmid":"31882321","id":"PMC_31882321","title":"Coactivation of Endogenous Wnt10b and Foxc2 by CRISPR Activation Enhances BMSC Osteogenesis and Promotes Calvarial Bone Regeneration.","date":"2019","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31882321","citation_count":54,"is_preprint":false},{"pmid":"29216867","id":"PMC_29216867","title":"Protein kinase C α enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin.","date":"2017","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29216867","citation_count":53,"is_preprint":false},{"pmid":"33505426","id":"PMC_33505426","title":"YTHDF2 Inhibits Gastric Cancer Cell Growth by Regulating FOXC2 Signaling Pathway.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33505426","citation_count":52,"is_preprint":false},{"pmid":"32510325","id":"PMC_32510325","title":"Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/32510325","citation_count":51,"is_preprint":false},{"pmid":"32249539","id":"PMC_32249539","title":"Circular RNA PVT1 promotes metastasis via regulating of miR-526b/FOXC2 signals in OS cells.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32249539","citation_count":51,"is_preprint":false},{"pmid":"12453913","id":"PMC_12453913","title":"FOXC2 mRNA Expression and a 5' untranslated region polymorphism of the gene are associated with insulin resistance.","date":"2002","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/12453913","citation_count":51,"is_preprint":false},{"pmid":"29341903","id":"PMC_29341903","title":"Emerging roles and mechanisms of FOXC2 in cancer.","date":"2018","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29341903","citation_count":50,"is_preprint":false},{"pmid":"24700685","id":"PMC_24700685","title":"Inorganic phosphate induces cancer cell mediated angiogenesis dependent on forkhead box protein C2 (FOXC2) regulated osteopontin expression.","date":"2014","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24700685","citation_count":50,"is_preprint":false},{"pmid":"30633332","id":"PMC_30633332","title":"H19 and Foxc2 synergistically promotes osteogenic differentiation of BMSCs via Wnt-β-catenin pathway.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30633332","citation_count":49,"is_preprint":false},{"pmid":"30722065","id":"PMC_30722065","title":"Structural basis for DNA recognition by FOXC2.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/30722065","citation_count":46,"is_preprint":false},{"pmid":"20460685","id":"PMC_20460685","title":"p120-catenin is transcriptionally downregulated by FOXC2 in non-small cell lung cancer cells.","date":"2010","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/20460685","citation_count":44,"is_preprint":false},{"pmid":"35637250","id":"PMC_35637250","title":"Glioblastoma-associated microglia-derived exosomal circKIF18A promotes angiogenesis by targeting FOXC2.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35637250","citation_count":43,"is_preprint":false},{"pmid":"32513911","id":"PMC_32513911","title":"LncRNA FOXC2-AS1 enhances FOXC2 mRNA stability to promote colorectal cancer progression via activation of Ca2+-FAK signal pathway.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32513911","citation_count":42,"is_preprint":false},{"pmid":"26113535","id":"PMC_26113535","title":"Foxc2 enhances proliferation and inhibits apoptosis through activating Akt/mTORC1 signaling pathway in mouse preadipocytes.","date":"2015","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/26113535","citation_count":42,"is_preprint":false},{"pmid":"28253399","id":"PMC_28253399","title":"Foxc1 and Foxc2 in the Neural Crest Are Required for Ocular Anterior Segment Development.","date":"2017","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/28253399","citation_count":42,"is_preprint":false},{"pmid":"28433696","id":"PMC_28433696","title":"FOXC2 positively regulates YAP signaling and promotes the glycolysis of nasopharyngeal carcinoma.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/28433696","citation_count":42,"is_preprint":false},{"pmid":"32110058","id":"PMC_32110058","title":"FOXC2 Promotes Oxaliplatin Resistance by Inducing Epithelial-Mesenchymal Transition via MAPK/ERK Signaling in Colorectal Cancer.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32110058","citation_count":41,"is_preprint":false},{"pmid":"26079578","id":"PMC_26079578","title":"Combining Foxc2 and Connexin37 deletions in mice leads to severe defects in lymphatic vascular growth and remodeling.","date":"2015","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/26079578","citation_count":41,"is_preprint":false},{"pmid":"28925407","id":"PMC_28925407","title":"Foxc2 coordinates inflammation and browning of white adipose by leptin-STAT3-PRDM16 signal in mice.","date":"2017","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/28925407","citation_count":40,"is_preprint":false},{"pmid":"34324140","id":"PMC_34324140","title":"FOXC2-AS1 stabilizes FOXC2 mRNA via association with NSUN2 in gastric cancer cells.","date":"2021","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/34324140","citation_count":38,"is_preprint":false},{"pmid":"15906099","id":"PMC_15906099","title":"Lymphoedema-distichiasis and FOXC2: unreported mutations, de novo mutation estimate, families without coding mutations.","date":"2005","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15906099","citation_count":38,"is_preprint":false},{"pmid":"37499655","id":"PMC_37499655","title":"FOXC2 promotes vasculogenic mimicry and resistance to anti-angiogenic therapy.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37499655","citation_count":37,"is_preprint":false},{"pmid":"23645207","id":"PMC_23645207","title":"Foxc2 induces Wnt4 and Bmp4 expression during muscle regeneration and osteogenesis.","date":"2013","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/23645207","citation_count":37,"is_preprint":false},{"pmid":"20431116","id":"PMC_20431116","title":"Notch signaling, wt1 and foxc2 are key regulators of the podocyte gene regulatory network in Xenopus.","date":"2010","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20431116","citation_count":37,"is_preprint":false},{"pmid":"23300339","id":"PMC_23300339","title":"BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation.","date":"2013","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/23300339","citation_count":37,"is_preprint":false},{"pmid":"25587036","id":"PMC_25587036","title":"Notch1 acts via Foxc2 to promote definitive hematopoiesis via effects on hemogenic endothelium.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25587036","citation_count":37,"is_preprint":false},{"pmid":"26953188","id":"PMC_26953188","title":"Segregated Foxc2, NFATc1 and Connexin expression at normal developing venous valves, and Connexin-specific differences in the valve phenotypes of Cx37, Cx43, and Cx47 knockout mice.","date":"2016","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/26953188","citation_count":37,"is_preprint":false},{"pmid":"24122419","id":"PMC_24122419","title":"Foxc2 over-expression in bone marrow mesenchymal stem cells stimulates osteogenic differentiation and inhibits adipogenic differentiation.","date":"2014","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24122419","citation_count":36,"is_preprint":false},{"pmid":"22522965","id":"PMC_22522965","title":"Generation of conditional alleles for Foxc1 and Foxc2 in mice.","date":"2012","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/22522965","citation_count":35,"is_preprint":false},{"pmid":"11943768","id":"PMC_11943768","title":"Mechanisms of FOXC2- and FOXD1-mediated regulation of the RI alpha subunit of cAMP-dependent protein kinase include release of transcriptional repression and activation by protein kinase B alpha and cAMP.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11943768","citation_count":35,"is_preprint":false},{"pmid":"23878394","id":"PMC_23878394","title":"Phosphorylation regulates FOXC2-mediated transcription in lymphatic endothelial cells.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23878394","citation_count":34,"is_preprint":false},{"pmid":"31464093","id":"PMC_31464093","title":"FOXC2 expression and epithelial-mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer.","date":"2019","source":"The journal of pathology. Clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/31464093","citation_count":33,"is_preprint":false},{"pmid":"30389560","id":"PMC_30389560","title":"Long noncoding RNA FOXC2-AS1 facilitates the proliferation and progression of prostate cancer via targeting miR-1253/EZH2.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30389560","citation_count":33,"is_preprint":false},{"pmid":"19540201","id":"PMC_19540201","title":"The forkhead transcription factor Foxc2 stimulates osteoblast differentiation.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19540201","citation_count":33,"is_preprint":false},{"pmid":"27654511","id":"PMC_27654511","title":"Cyclooxygenase-2 induced β1-integrin expression in NSCLC and promoted cell invasion via the EP1/MAPK/E2F-1/FoxC2 signal pathway.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27654511","citation_count":33,"is_preprint":false},{"pmid":"12383817","id":"PMC_12383817","title":"Lymphedema-distichiasis syndrome and FOXC2 gene mutation.","date":"2002","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/12383817","citation_count":32,"is_preprint":false},{"pmid":"22374725","id":"PMC_22374725","title":"Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype.","date":"2012","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/22374725","citation_count":32,"is_preprint":false},{"pmid":"22174714","id":"PMC_22174714","title":"The Role of FoxC2 Transcription Factor in Tumor Angiogenesis.","date":"2011","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22174714","citation_count":32,"is_preprint":false},{"pmid":"23815774","id":"PMC_23815774","title":"Foxc2 regulates osteogenesis and angiogenesis of bone marrow mesenchymal stem cells.","date":"2013","source":"BMC musculoskeletal disorders","url":"https://pubmed.ncbi.nlm.nih.gov/23815774","citation_count":31,"is_preprint":false},{"pmid":"12485195","id":"PMC_12485195","title":"FOXC2 truncating mutation in distichiasis, lymphedema, and cleft palate.","date":"2002","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12485195","citation_count":31,"is_preprint":false},{"pmid":"28724617","id":"PMC_28724617","title":"Human venous valve disease caused by mutations in FOXC2 and GJC2.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28724617","citation_count":31,"is_preprint":false},{"pmid":"11585339","id":"PMC_11585339","title":"Bone morphogenetic protein regulation of forkhead/winged helix transcription factor Foxc2 (Mfh1) in a murine mesodermal cell line C1 and in skeletal precursor cells.","date":"2001","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/11585339","citation_count":31,"is_preprint":false},{"pmid":"26808710","id":"PMC_26808710","title":"Arterialization and anomalous vein wall remodeling in varicose veins is associated with upregulated FoxC2-Dll4 pathway.","date":"2016","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26808710","citation_count":30,"is_preprint":false},{"pmid":"29380370","id":"PMC_29380370","title":"Endothelial immune activation programmes cell-fate decisions and angiogenesis by inducing angiogenesis regulator DLL4 through TLR4-ERK-FOXC2 signalling.","date":"2018","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29380370","citation_count":30,"is_preprint":false},{"pmid":"27336949","id":"PMC_27336949","title":"Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.","date":"2016","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27336949","citation_count":30,"is_preprint":false},{"pmid":"25822012","id":"PMC_25822012","title":"Downregulation of FoxC2 Increased Susceptibility to Experimental Colitis: Influence of Lymphatic Drainage Function?","date":"2015","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25822012","citation_count":28,"is_preprint":false},{"pmid":"27276711","id":"PMC_27276711","title":"FOXC2 disease-mutations identified in lymphedema-distichiasis patients cause both loss and gain of protein function.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27276711","citation_count":27,"is_preprint":false},{"pmid":"9169153","id":"PMC_9169153","title":"Isolation of the mouse (MFH-1) and human (FKHL 14) mesenchyme fork head-1 genes reveals conservation of their gene and protein structures.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9169153","citation_count":26,"is_preprint":false},{"pmid":"30302523","id":"PMC_30302523","title":"FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.","date":"2018","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30302523","citation_count":26,"is_preprint":false},{"pmid":"24278289","id":"PMC_24278289","title":"FOXC2 mutations in familial and sporadic spinal extradural arachnoid cyst.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24278289","citation_count":26,"is_preprint":false},{"pmid":"27819350","id":"PMC_27819350","title":"α-MSH and Foxc2 promote fatty acid oxidation through C/EBPβ negative transcription in mice adipose tissue.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27819350","citation_count":26,"is_preprint":false},{"pmid":"37154714","id":"PMC_37154714","title":"Endothelial FOXC1 and FOXC2 promote intestinal regeneration after ischemia-reperfusion injury.","date":"2023","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/37154714","citation_count":25,"is_preprint":false},{"pmid":"32271448","id":"PMC_32271448","title":"LncRNA FOXC2-AS1 regulated proliferation and apoptosis of vascular smooth muscle cell through targeting miR-1253/FOXF1 axis in atherosclerosis.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32271448","citation_count":25,"is_preprint":false},{"pmid":"25486430","id":"PMC_25486430","title":"Casein kinase 2 prevents mesenchymal transformation by maintaining Foxc2 in the cytoplasm.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25486430","citation_count":25,"is_preprint":false},{"pmid":"27064522","id":"PMC_27064522","title":"FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27064522","citation_count":23,"is_preprint":false},{"pmid":"14566319","id":"PMC_14566319","title":"Mutation of the FOXC2 gene in familial distichiasis.","date":"2003","source":"Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus","url":"https://pubmed.ncbi.nlm.nih.gov/14566319","citation_count":22,"is_preprint":false},{"pmid":"30376688","id":"PMC_30376688","title":"Foxc2 is required for proper cardiac neural crest cell migration, outflow tract septation, and ventricle expansion.","date":"2018","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/30376688","citation_count":22,"is_preprint":false},{"pmid":"21667821","id":"PMC_21667821","title":"FOXC2 transcription factor: a novel regulator of lymphangiogenesis.","date":"2011","source":"Lymphology","url":"https://pubmed.ncbi.nlm.nih.gov/21667821","citation_count":21,"is_preprint":false},{"pmid":"27283491","id":"PMC_27283491","title":"FOXC2 and CLIP4 : a potential biomarker for synchronous metastasis of ≤7-cm clear cell renal cell carcinomas.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27283491","citation_count":21,"is_preprint":false},{"pmid":"10722840","id":"PMC_10722840","title":"MFH-1 is required for bone morphogenetic protein-2-induced osteoblastic differentiation of C2C12 myoblasts.","date":"2000","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10722840","citation_count":20,"is_preprint":false},{"pmid":"28223138","id":"PMC_28223138","title":"Foxc1 and Foxc2 are necessary to maintain glomerular podocytes.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/28223138","citation_count":20,"is_preprint":false},{"pmid":"15198934","id":"PMC_15198934","title":"Expression of FOXC2 in adipose and muscle and its association with whole body insulin sensitivity.","date":"2004","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15198934","citation_count":18,"is_preprint":false},{"pmid":"19548265","id":"PMC_19548265","title":"Abnormal Shh and FOXC2 expression correlates with aberrant lymphatic development in human fetuses with increased nuchal translucency.","date":"2009","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/19548265","citation_count":18,"is_preprint":false},{"pmid":"30147726","id":"PMC_30147726","title":"Foxc2 and BMP2 Induce Osteogenic/Odontogenic Differentiation and Mineralization of Human Stem Cells from Apical Papilla.","date":"2018","source":"Stem cells international","url":"https://pubmed.ncbi.nlm.nih.gov/30147726","citation_count":17,"is_preprint":false},{"pmid":"24406047","id":"PMC_24406047","title":"FOXC2 often overexpressed in glioblastoma enhances proliferation and invasion in glioblastoma cells.","date":"2013","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/24406047","citation_count":17,"is_preprint":false},{"pmid":"32170602","id":"PMC_32170602","title":"Foxc2 Alleviates Ox-LDL-Induced Lipid Accumulation, Inflammation, and Apoptosis of Macrophage via Regulating the Expression of Angptl2.","date":"2020","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/32170602","citation_count":17,"is_preprint":false},{"pmid":"25573594","id":"PMC_25573594","title":"FOXC2 expression is associated with tumor proliferation and invasion potential in oral tongue squamous cell carcinoma.","date":"2015","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/25573594","citation_count":16,"is_preprint":false},{"pmid":"27193493","id":"PMC_27193493","title":"Characterization of Kidney and Skeleton Phenotypes of Mice Double Heterozygous for Foxc1 and Foxc2.","date":"2016","source":"Cells, tissues, organs","url":"https://pubmed.ncbi.nlm.nih.gov/27193493","citation_count":16,"is_preprint":false},{"pmid":"31801629","id":"PMC_31801629","title":"FOXC2-AS1 regulates phenotypic transition, proliferation and migration of human great saphenous vein smooth muscle cells.","date":"2019","source":"Biological research","url":"https://pubmed.ncbi.nlm.nih.gov/31801629","citation_count":16,"is_preprint":false},{"pmid":"32698337","id":"PMC_32698337","title":"FOXC2 Disease Mutations Identified in Lymphedema Distichiasis Patients Impair Transcriptional Activity and Cell Proliferation.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32698337","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50295,"output_tokens":10475,"usd":0.154005,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21293,"output_tokens":6872,"usd":0.139132,"stage2_stop_reason":"end_turn"},"total_usd":0.293137,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"MFH-1 (FOXC2) encodes a forkhead domain protein that binds the HNF3 binding site, acting as a DNA-binding transcription factor expressed in developing mesenchyme.\",\n      \"method\": \"Recombinant protein DNA-binding assay (HNF3 binding site); expression analysis in embryos\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct in vitro DNA-binding demonstrated with recombinant protein, single lab, single method\",\n      \"pmids\": [\"8325367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"FOXC2 (MFH-1) protein acts as a positive transactivator; both mouse and human MFH-1 proteins have transcriptional activation activity. The gene has no introns and mouse/human proteins share 94% amino acid identity.\",\n      \"method\": \"Transcriptional activity assay (transfection-based reporter); gene structure determination\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct transactivation assay, single lab, single method\",\n      \"pmids\": [\"9169153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Loss of FOXC2 (MFH-1) in mice causes interrupted aortic arch and craniofacial/vertebral skeletal defects, establishing an essential role in neural-crest-derived aortic arch remodeling and skeletogenesis.\",\n      \"method\": \"Targeted gene knockout in mice; histological and anatomical phenotype analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — constitutive knockout with defined developmental phenotype, replicated across multiple knockout studies\",\n      \"pmids\": [\"9409679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Haploinsufficiency of FOXC2 (via nonsense and frameshift mutations) causes lymphedema-distichiasis syndrome in humans, establishing FOXC2 as a dosage-sensitive transcription factor required for lymphatic development.\",\n      \"method\": \"Human mutation analysis (sequencing of FOXC2 coding region in LD families); functional inference from loss-of-function mutations\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple independent families with inactivating mutations, replicated across many subsequent studies\",\n      \"pmids\": [\"11078474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"FOXC2 (MFH-1) is required for BMP-2-induced osteoblastic differentiation of C2C12 myoblasts; antisense suppression of MFH-1 reduced BMP-2-induced alkaline phosphatase activity and osteocalcin production.\",\n      \"method\": \"Antisense stable transfection in C2C12 cells; alkaline phosphatase assay; osteocalcin measurement\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — loss-of-function with defined cellular phenotype, single lab, single method\",\n      \"pmids\": [\"10722840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Overexpression of FOXC2 in adipocytes increases sensitivity of the beta-adrenergic–cAMP–PKA signaling pathway by altering adipocyte PKA holoenzyme composition, leading to a lean and insulin-sensitive phenotype in transgenic mice.\",\n      \"method\": \"Transgenic mouse overexpression; biochemical PKA holoenzyme composition analysis; metabolic phenotyping\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — transgenic model with biochemical mechanism (PKA holoenzyme), multiple metabolic readouts, highly cited foundational study\",\n      \"pmids\": [\"11551504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Foxc1 and Foxc2 have dose-dependent cooperative roles in somitogenesis; compound homozygous Foxc1;Foxc2 mutants show complete absence of segmented paraxial mesoderm and require both genes for transcription of paraxis, Mesp1, Mesp2, Hes5, and Notch1 in anterior presomitic mesoderm.\",\n      \"method\": \"Compound genetic knockout in mice; in situ hybridization for downstream target genes; genetic epistasis analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — compound mutant genetic epistasis with multiple molecular readouts, replicated across compound heterozygotes\",\n      \"pmids\": [\"11562355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"FOXC2 and FOXD1 specifically activate the 1b promoter of the PKA RIα subunit gene in adipocytes; FOXC2 acts by releasing a transcriptional repressor from an upstream region, and protein kinase B alpha/Akt1 cooperates to enhance this activation.\",\n      \"method\": \"Promoter deletion mapping; bandshift (EMSA) assays; co-transfection reporter assays in 3T3-L1 adipocytes and Sertoli cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — EMSA plus reporter assays with deletion mapping, two orthogonal methods, single lab\",\n      \"pmids\": [\"11943768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"BMP-2 and BMP-4/7 treatment of mesodermal progenitor C1 cells and limb mesenchyme upregulates Mfh1/Foxc2 expression; BMP-7 implantation in limb bud organ culture induces Mfh1 expression, placing FOXC2 downstream of BMP signaling in skeletal precursors.\",\n      \"method\": \"In vitro BMP treatment of cell lines; in situ hybridization; limb bud organ culture with BMP protein implantation\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vitro and ex vivo methods, single lab, consistent results across models\",\n      \"pmids\": [\"11585339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"FoxC2 blocks adipogenesis in 3T3-L1 preadipocytes by inhibiting PPARγ-mediated expression of a subset of adipogenic genes (C/EBPα, adiponectin, perilipin) without affecting PPARγ DNA binding or transactivation from a PPARγ response element.\",\n      \"method\": \"Overexpression in 3T3-L1 cells and Swiss fibroblasts; immunoblotting; PPARγ transactivation reporter assay; PPARγ DNA-binding assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple cellular assays and reporter assays with mechanistic resolution, single lab\",\n      \"pmids\": [\"15277530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Foxc1 and Foxc2 negatively regulate intermediate mesoderm formation and drive paraxial mesoderm cell fate specification; their misexpression in prospective intermediate mesoderm causes cells to acquire paraxial (somite) fate markers Pax7 and Paraxis.\",\n      \"method\": \"Mouse double knockout phenotyping; chick gain-of-function electroporation; in situ hybridization for lineage markers\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — complementary loss- and gain-of-function in two model systems with molecular readouts\",\n      \"pmids\": [\"15196959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FOXC2 is induced downstream of EMT-triggering signals (TGF-β1, Snail, Twist, Goosecoid) and is required for metastasis of murine mammary carcinoma cells to the lung; overexpression of FOXC2 enhances metastatic ability.\",\n      \"method\": \"Gene expression profiling; shRNA knockdown; FOXC2 overexpression in mammary carcinoma cells; in vivo lung metastasis assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo loss- and gain-of-function with defined metastatic phenotype, multiple EMT inducers tested\",\n      \"pmids\": [\"17537911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Foxc2 directly activates the Ang-2 (angiopoietin-2) promoter in adipocytes; transgenic overexpression of FOXC2 in adipose tissue causes altered vascular patterning that is almost completely reversed by an Ang-2-specific antagonist.\",\n      \"method\": \"Transgenic mouse model; promoter luciferase reporter assay (direct activation of Ang-2 promoter); pharmacological antagonist rescue\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct promoter activation assay combined with in vivo genetic and pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"18621714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Foxc2 directly regulates integrin beta3 (Itgb3) expression through multiple forkhead-binding elements within the Itgb3 promoter; Foxc2 overexpression enhances endothelial cell migration and adhesion, an effect blocked by Itgb3 neutralizing antibody, and promotes microvessel outgrowth in ex vivo aortic ring assay.\",\n      \"method\": \"Gene expression profiling; promoter reporter assay with forkhead-binding element mapping; Itgb3 neutralizing antibody; Foxc2 heterozygous mutant mouse endothelial cells; ex vivo aortic ring assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct promoter binding mapped, loss-of-function in primary cells, ex vivo functional assay, multiple orthogonal methods\",\n      \"pmids\": [\"18579532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FOXC2 transcriptionally represses p120-catenin (CTNND1) in non-small cell lung cancer cells by directly binding the p120ctn promoter between positions +267 and +282, as shown by EMSA; FOXC2 knockdown increases p120ctn expression and E-cadherin levels.\",\n      \"method\": \"Luciferase reporter assay with serial promoter deletions; EMSA (electrophoretic mobility shift assay); RNAi knockdown; immunoblotting\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct DNA binding confirmed by EMSA, promoter deletion mapping, and loss-of-function rescue, multiple orthogonal methods\",\n      \"pmids\": [\"20460685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In Xenopus, foxc2 functions in a transcriptional network for podocyte specification; combined knockdown of wt1 and foxc2 abolishes all podocyte marker gene expression, and co-expression of wt1 and foxc2 increases podocyte gene expression, with Notch signaling required for ectopic induction.\",\n      \"method\": \"Antisense morpholino knockdown in Xenopus; gain-of-function overexpression; in situ hybridization; genetic epistasis analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic loss- and gain-of-function in multiple combinations with defined molecular readouts, two orthogonal approaches\",\n      \"pmids\": [\"20431116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PROX1 and FOXC2 cooperate with shear stress/mechanotransduction to control expression of connexin37 and activation of calcineurin/NFAT signaling during lymphatic valve formation; connexin37 and calcineurin are required for valve territory assembly.\",\n      \"method\": \"In vitro shear stress assay on lymphatic endothelial cells; knockdown of PROX1 and FOXC2; analysis of connexin37 expression and calcineurin/NFAT signaling; mouse developmental genetics\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic pathway dissection combining cell-based shear stress assays with in vivo mouse genetics and molecular signaling readouts\",\n      \"pmids\": [\"22306086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FOXC2 induces Wnt4 expression by directly interacting with the Wnt4 promoter region, leading to elevated BMP4 and RhoA-GTP, which inhibits myoblast fusion; sustained FOXC2 expression redirects myoblast commitment toward osteogenesis.\",\n      \"method\": \"Chromatin immunoprecipitation; promoter reporter assay; gain- and loss-of-function in C2C12 myoblasts; osteogenic differentiation assay\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP confirms direct promoter binding, overexpression/knockdown with defined phenotype, single lab\",\n      \"pmids\": [\"23645207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FOXC2 expression confers cancer stem cell (CSC) properties and spontaneous metastasis; FOXC2 transcriptionally regulates PDGFR-β, and PDGFR inhibition with sunitinib reduces CSC and metastatic properties of FOXC2-expressing tumor cells.\",\n      \"method\": \"Lentiviral shRNA knockdown; FOXC2 overexpression; mammosphere-forming assay; tumor initiation assay; gene expression profiling; pharmacological inhibition\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays with loss- and gain-of-function, PDGFR-β identified as downstream target, single lab\",\n      \"pmids\": [\"23378344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BSTA promotes mTORC2-mediated phosphorylation of Akt1 at Ser473, which suppresses FoxC2 expression to promote adipocyte differentiation; BSTA-Akt1 interaction is required for this mTORC2-BSTA-Akt1-FoxC2 signaling mechanism.\",\n      \"method\": \"Gene-trap murine embryonic stem cells; co-immunoprecipitation (BSTA-Akt1 complex); phosphorylation assays; FoxC2 expression analysis; adipocyte differentiation assay\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — co-IP of complex, phosphorylation assay, genetic loss-of-function, multiple orthogonal methods establishing pathway\",\n      \"pmids\": [\"23300339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SENP3-mediated de-SUMOylation of FOXC2 enhances its transcriptional activity; FOXC2 is a substrate of the SUMO2/3-specific protease SENP3, and a SUMO-less FOXC2 transcriptionally activates N-cadherin expression to promote EMT in gastric cancer.\",\n      \"method\": \"Co-immunoprecipitation; SUMO substrate biochemical assay; SENP3 overexpression/knockdown; N-cadherin promoter reporter; cell migration assay; nude mouse xenograft\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — biochemical identification of FOXC2 as SENP3 substrate, co-IP, reporter assay, functional phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"25216525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FOXC2 phosphorylation on eight evolutionarily conserved proline-directed serine/threonine residues regulates its transcriptional activity in lymphatic endothelial cells; phosphorylation controls selective FOXC2 recruitment to chromatin, and a phosphorylation-deficient mutant fails to induce vascular remodeling in vivo.\",\n      \"method\": \"Genome-wide ChIP-seq (location analysis) in lymphatic endothelial cells; phospho-mutant FOXC2 constructs; in vivo vascular remodeling assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genome-wide chromatin occupancy analysis, site-directed mutagenesis, in vivo functional validation, multiple orthogonal methods\",\n      \"pmids\": [\"23878394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FOXC2 directly binds the MET promoter to increase its transcriptional activity, activating the HGF-MET signaling pathway to promote colorectal cancer invasion and metastasis.\",\n      \"method\": \"Luciferase reporter assay; chromatin immunoprecipitation (ChIP); FOXC2 overexpression; MET inhibition rescue; orthotopic mouse metastasis model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct promoter binding confirmed by ChIP and luciferase, MET inhibition rescue, in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"25381815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Casein kinase 2 (CK2) associates with FOXC2 and phosphorylates it at serine 124, retaining FOXC2 in the cytoplasm of normal epithelial cells; CK2 inhibition or downregulation of CK2β causes nuclear accumulation of FOXC2 and mesenchymal gene expression.\",\n      \"method\": \"In vitro kinase assay (CK2 phosphorylation of FOXC2 at S124); co-immunoprecipitation (CK2-FOXC2 association); site-directed mutagenesis (S124L and S124D); CK2β knockdown; subcellular fractionation/immunofluorescence; cell migration assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay, co-IP, phospho-site mutagenesis with functional readout, subcellular localization experiments, multiple orthogonal methods\",\n      \"pmids\": [\"25486430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FOXC2 directly binds the p120-catenin promoter and transcriptionally represses it, with PKCα acting upstream of FOXC2 in this signaling axis; loss of p120-catenin destabilizes E-cadherin at adherens junctions and promotes cell migration.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP); dual luciferase promoter assay; PKCα and FOXC2 knockdown; immunofluorescence of E-cadherin/p120-catenin localization; transwell migration/invasion assays\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP confirms direct promoter binding, luciferase reporter, knockdown with cellular phenotype, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"29216867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FOXC2 inactivation in lymphatic endothelial cells causes abnormal shear stress sensing, promotes junction disassembly and cell cycle entry; loss of FOXC2-dependent quiescence is mediated by the Hippo pathway transcriptional coactivator TAZ, leading to cell death and vascular lumen collapse.\",\n      \"method\": \"Inducible endothelial-specific Foxc2 deletion in mice; in vitro shear stress assay; TAZ pathway analysis; cell junction and cytoskeleton imaging; cell cycle analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible conditional knockout with defined molecular mechanism (TAZ), in vitro and in vivo orthogonal approaches\",\n      \"pmids\": [\"26389677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FOXC2 and FOXC1 regulate ERK signaling in lymphatic vessel growth; LEC-specific deletion of Foxc1, Foxc2, or both results in increased LEC proliferation and aberrant expression of Ras regulators leading to ERK hyperactivation; pharmacological ERK inhibition rescues the enlarged lymphatic vessel phenotype.\",\n      \"method\": \"LEC-specific conditional knockout in mice; embryonic phenotyping; ERK activation assays; pharmacological ERK inhibition in utero\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional knockout with defined molecular pathway, pharmacological rescue, multiple genetic combinations tested\",\n      \"pmids\": [\"27214551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FOXF2 directly targets the FOXC2 promoter to negatively regulate FOXC2 transcription in basal-like breast cancer cells; FOXC2 mediates FOXF2-regulated EMT phenotype and multidrug resistance.\",\n      \"method\": \"Promoter reporter assay; FOXF2 overexpression/knockdown with FOXC2 expression readout; EMT and drug resistance phenotyping\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter assay plus functional rescue experiments, single lab, two orthogonal methods\",\n      \"pmids\": [\"26210254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"p38MAPK signaling promotes FOXC2 expression in prostate cancer; inhibition of p38 using a p38 inhibitor reduces FOXC2 levels, restores epithelial attributes and androgen deprivation therapy sensitivity, and reduces circulating tumor cells in vivo.\",\n      \"method\": \"p38 inhibitor treatment; FOXC2 expression analysis; in vivo tumor model with drug treatment; flow cytometry for circulating tumor cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway placement with in vivo functional readout, single lab\",\n      \"pmids\": [\"26804168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Foxc2 and Connexin37 function in a common developmental pathway for lymphatic valve formation; Foxc2(+/-); Cx37(-/-) compound mutant mice display severe lymphatic defects not seen in single mutants, including absence of lymphatic valves.\",\n      \"method\": \"Compound genetic knockout in mice (Foxc2+/-;Cx37-/-); lymphatic vascular phenotyping; quantitative morphometry\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis via compound mutant showing synthetic lethality/phenotype, rigorous quantitative documentation\",\n      \"pmids\": [\"26079578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Notch signaling acts upstream of Foxc2 in hemogenic endothelial cells to promote definitive hematopoiesis; Foxc2 is a highly upregulated Notch target in hemogenic endothelium, and loss of Foxc2 orthologs in zebrafish and mice impairs definitive hematopoiesis.\",\n      \"method\": \"Mouse embryonic stem cell differentiation with Notch induction; zebrafish morpholino knockdown; mouse embryo analysis; transcriptional profiling identifying Foxc2 as Notch target\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis established in two model organisms (mouse and zebrafish) with defined pathway placement\",\n      \"pmids\": [\"25587036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FOXC2 disease-causing mutations outside the forkhead domain cause either loss or gain of transactivation activity at FOXC1/FOXC2 response elements; a frameshift mutant protein is sequestered in nuclear aggregates while all mutants retain nuclear localization.\",\n      \"method\": \"Subcellular localization (immunofluorescence); transactivation reporter assay on FOXC1/FOXC2 response elements; analysis of six patient-derived mutations\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay and localization studies with six independent mutations, two orthogonal methods, single lab\",\n      \"pmids\": [\"27276711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FOXC1 and FOXC2 differentially regulate cytoskeletal activity in lymphatic valves: FOXC1 knockdown increases focal adhesions and actin stress fibers, while FOXC2 knockdown increases focal adherens and disrupts cell junctions via increased ROCK activation; ROCK inhibition rescues these defects.\",\n      \"method\": \"siRNA knockdown of FOXC1 and FOXC2 in human lymphatic endothelial cells; inducible endothelial-specific deletion in mice; ROCK inhibitor treatment; cytoskeletal imaging; valve phenotyping\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro mechanistic dissection with pharmacological rescue, validated in vivo, multiple orthogonal methods\",\n      \"pmids\": [\"32510325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TLR4 signaling induces ERK phosphorylation, which leads to FOXC2-ERK protein interaction, ERK-dependent phosphorylation of FOXC2 on serine/threonine residues, and subsequent FOXC2 binding to the DLL4 promoter to activate DLL4 transcription and inflammatory angiogenesis.\",\n      \"method\": \"Co-immunoprecipitation (FOXC2-ERK); ChIP (FOXC2 binding to DLL4 promoter); ERK dominant-negative transfection; FOXC2-siRNA; pharmacological ERK inhibition; in vivo LPS mouse model\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — co-IP, ChIP, mutagenesis, and in vivo genetic/pharmacological approaches, multiple orthogonal methods\",\n      \"pmids\": [\"29380370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOXC2 interacts with YAP and TEAD to activate YAP signaling, and this FOXC2-YAP pathway positively regulates expression of Hexokinase 2 (HK2) to promote glycolysis in nasopharyngeal carcinoma cells.\",\n      \"method\": \"Co-immunoprecipitation (FOXC2 with YAP and TEAD); HK2 expression analysis; FOXC2/YAP knockdown; metabolic (glycolysis) assay; in vivo xenograft\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP establishes protein-protein interaction, functional readout with glycolysis assay, single lab\",\n      \"pmids\": [\"28433696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Foxc2 inhibits LPS-induced inflammation in white adipose tissue via the leptin-JAK2/STAT3 pathway; STAT3 physically interacts with PRDM16 to form a complex that promotes WAT browning; Foxc2 overexpression ameliorates inflammation and promotes adipose browning in obese mice.\",\n      \"method\": \"Co-immunoprecipitation (STAT3-PRDM16 complex); ChIP (Foxc2 binding to CREB/leptin promoter region); Foxc2 overexpression in vivo; LPS-induced inflammatory model\",\n      \"journal\": \"International journal of obesity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP of STAT3-PRDM16 complex and ChIP, in vivo overexpression model, single lab\",\n      \"pmids\": [\"28925407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structures of the FOXC2 DNA-binding domain (DBD) in complex with DNA revealed that helix H3 makes all base-specific contacts, while the N-terminus, wing 1, and C-terminus make additional phosphate contacts; structural and biochemical analyses revised the previously proposed DNA recognition mechanism.\",\n      \"method\": \"X-ray crystallography (two crystal structures with different DNA sites); biochemical DNA-binding assays; bioinformatics analysis of disease mutations\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with functional biochemical validation and mechanistic interpretation, rigorous structural biology\",\n      \"pmids\": [\"30722065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Foxc2 overexpression in BMSCs promotes osteogenesis and represses adipogenesis via activation of canonical Wnt-β-catenin signaling; XAV939 (Wnt-β-catenin pathway inhibitor) suppresses Foxc2-mediated differentiation.\",\n      \"method\": \"Lentiviral Foxc2 overexpression in rabbit BMSCs; osteogenic/adipogenic differentiation assays; β-catenin/TCF-LEF reporter assay; pharmacological inhibitor (XAV939)\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — overexpression with pharmacological pathway validation and reporter assay, single lab\",\n      \"pmids\": [\"24122419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"H19 lncRNA binds to Foxc2 protein (RNA-protein interaction); H19/Foxc2 synergistically regulate Wnt4 promoter expression; Foxc2 binds to the Wnt4 promoter and promotes its transcription to drive BMSC osteogenic differentiation via Wnt-β-catenin pathway.\",\n      \"method\": \"RNA immunoprecipitation; RNA pull-down; ChIP (Foxc2 binding to Wnt4 promoter); overexpression/knockdown; osteogenic differentiation assays\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP plus RIP/pull-down for protein-RNA interaction, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"30633332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FOXC2 disease mutations cause loss or gain of transactivation function and some mutant proteins are sequestered into nuclear aggregates causing cell death, providing molecular basis for lymphedema distichiasis pathogenesis.\",\n      \"method\": \"Subcellular localization (immunofluorescence); transactivation reporter assay; cell viability assay; analysis of nine patient-derived mutations\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay and localization/viability assays across multiple mutations, two orthogonal methods, single lab\",\n      \"pmids\": [\"32698337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Foxc2 inactivation in adult lymphatic endothelium compromises gut epithelial barrier, promotes dysbiosis and bacterial translocation, increases angiopoietin-2, and skews lymphatic endothelial subset specialization toward pro-fibrotic identities; commensal microbiota depletion rescues systemic inflammation and improves survival.\",\n      \"method\": \"Inducible adult-specific Foxc2 deletion in mice; single-cell atlas of lymphatic endothelial subtypes; microbiome analysis; microbiota depletion rescue experiment\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible conditional knockout with single-cell resolution, microbiota rescue validation, defined mechanistic pathway\",\n      \"pmids\": [\"34272244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CircKIF18A (exosomal circRNA) binds to FOXC2 protein in brain endothelial cells, stabilizes FOXC2 and promotes its nuclear translocation; nuclear FOXC2 directly binds promoters of ITGB3, CXCR4, and DLL4 to upregulate their expression and activate PI3K/AKT signaling to promote glioblastoma angiogenesis.\",\n      \"method\": \"Co-immunoprecipitation (circKIF18A-FOXC2 RNA-protein interaction); ChIP (FOXC2 binding to ITGB3, CXCR4, DLL4 promoters); promoter reporter assays; gain/loss-of-function; in vivo tumorigenicity\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP confirms direct promoter binding, co-IP for protein-RNA interaction, functional in vivo validation, single lab\",\n      \"pmids\": [\"35637250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FOXC1 and FOXC2 in blood and lymphatic endothelial cells directly bind regulatory elements of CXCL12 and RSPO3 loci, respectively; loss of endothelial Foxc2 impairs RSPO3 expression in LECs, reducing Wnt signaling in intestinal stem cells and worsening ischemia-reperfusion injury; RSPO3 treatment rescues the damage.\",\n      \"method\": \"EC- and LEC-specific conditional Foxc2 knockout mice; ChIP (FOXC2 binding to CXCL12 and RSPO3 regulatory elements); rescue with recombinant CXCL12 and RSPO3; intestinal stem cell Wnt signaling assay\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP confirms direct binding, conditional genetic knockout in cell-type specific manner, ligand rescue validation, multiple orthogonal methods\",\n      \"pmids\": [\"37154714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FOXC2 promotes vasculogenic mimicry (VM) in solid tumors by driving ectopic expression of endothelial genes in tumor cells; this process is stimulated by hypoxia and VM-proficient tumors are resistant to anti-angiogenic therapy; suppression of Foxc2 augments anti-angiogenic response.\",\n      \"method\": \"FOXC2 overexpression/knockdown in diverse tumor cell lines; VM channel formation assay; hypoxia treatment; anti-angiogenic therapy combination in vivo\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss- and gain-of-function across multiple tumor types with defined VM phenotype and therapeutic readout, single lab\",\n      \"pmids\": [\"37499655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FOXC2 regulates G2/M cell cycle transition in cancer stem cell-enriched breast cancer cells; FOXC2 protein levels accumulate in G2 and decrease during mitosis; PLK1 activity is required for FOXC2 protein stability, and PLK1 inhibition reduces FOXC2 protein levels and sensitizes FOXC2-expressing CSC-enriched cells to PLK1 inhibitors.\",\n      \"method\": \"Cell cycle synchronization; FOXC2 protein level quantification at cell cycle stages; FOXC2 knockdown with cell cycle analysis; PLK1 inhibitor treatment; flow cytometry\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell cycle-resolved protein level measurement, pharmacological PLK1 inhibition, loss-of-function, single lab\",\n      \"pmids\": [\"27064522\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FOXC2 is a forkhead/winged-helix transcription factor that binds DNA through its helix H3-containing DBD (crystal structure resolved), activates or represses target gene promoters (MET, ITGB3, DLL4, Ang-2, Wnt4, p120-catenin, CXCL12, RSPO3, PKA RIα) through direct promoter occupancy, and is regulated post-translationally by CK2-mediated phosphorylation at Ser124 (controlling cytoplasmic vs. nuclear localization), by proline-directed phosphorylation (controlling chromatin recruitment), and by SENP3-mediated de-SUMOylation (enhancing transcriptional activity); it functions downstream of Notch, BMP, TGF-β, ERK/TLR4, and mTORC2-Akt signaling to control lymphatic valve formation and maintenance (via connexin37/calcineurin-NFAT and ROCK/cytoskeletal pathways), arterial specification, hematopoiesis, adipocyte metabolism (through PKA holoenzyme composition), osteogenesis (via Wnt-β-catenin), and EMT/metastasis (by inducing mesenchymal gene programs and cancer stem cell properties).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FOXC2 is a forkhead/winged-helix transcription factor that binds DNA through its forkhead domain and acts predominantly as a transcriptional activator across mesenchymal, endothelial, and metabolic programs [#0, #1, #36]. Crystal structures of its DNA-binding domain in complex with DNA establish that helix H3 makes all base-specific contacts while the N-terminus, wing 1, and C-terminus contribute phosphate contacts [#36]. In development, FOXC2 acts cooperatively with the paralog FOXC1 to specify paraxial mesoderm and drive somitogenesis through targets including paraxis, Mesp1/2, Hes5, and Notch1 [#6, #10], and its loss causes interrupted aortic arch and skeletal defects in mice [#2]. In humans, FOXC2 haploinsufficiency causes lymphedema-distichiasis syndrome, defining it as a dosage-sensitive regulator of lymphatic development [#3], and disease mutations alter transactivation or sequester the protein into nuclear aggregates [#31, #39]. FOXC2 is a central regulator of lymphatic valve formation and endothelial quiescence, operating through PROX1/connexin37/calcineurin-NFAT signaling under shear stress [#16, #29], through ROCK/cytoskeletal control of cell junctions [#32], and through restraint of TAZ-driven cell cycle entry and ERK hyperactivation [#25, #26]. It functions downstream of Notch in hemogenic endothelium to support definitive hematopoiesis [#30] and downstream of BMP signaling to promote osteoblastic differentiation [#4, #8] via Wnt-\\u03b2-catenin and Wnt4 induction [#37, #38, #17]. In adipocytes FOXC2 reprograms \\u03b2-adrenergic/cAMP/PKA signaling by altering PKA holoenzyme composition to produce a lean, insulin-sensitive phenotype [#5], directly activating the PKA RI\\u03b1 1b promoter [#7] and blocking PPAR\\u03b3-dependent adipogenesis [#9]. In cancer FOXC2 is induced by EMT-triggering signals and drives metastasis, cancer stem cell properties, and mesenchymal gene programs by directly occupying target promoters\\u2014activating MET, ITGB3, DLL4, and N-cadherin, and repressing p120-catenin [#11, #14, #22, #20, #24]. FOXC2 activity is tuned post-translationally by CK2 phosphorylation at Ser124 (controlling cytoplasmic versus nuclear localization) [#23], proline-directed phosphorylation that governs chromatin recruitment [#21], ERK-dependent phosphorylation linking TLR4 signaling to DLL4 activation [#33], and SENP3-mediated de-SUMOylation that enhances its transcriptional output [#20].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established the foundational molecular identity of FOXC2 as a sequence-specific DNA-binding forkhead protein, answering what class of factor it is.\",\n      \"evidence\": \"Recombinant protein DNA-binding to the HNF3 site and embryonic expression analysis\",\n      \"pmids\": [\"8325367\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vivo targets identified\", \"Transactivation versus repression not resolved\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Defined FOXC2 as a positive transactivator with high mouse/human conservation, framing it as a functional transcription factor rather than merely a DNA binder.\",\n      \"evidence\": \"Transfection-based reporter assays and gene structure determination\",\n      \"pmids\": [\"9169153\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No endogenous promoter targets defined\", \"Regulatory inputs unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrated an essential developmental role by showing knockout causes aortic arch and skeletal defects, placing FOXC2 in neural-crest-derived remodeling.\",\n      \"evidence\": \"Constitutive mouse knockout with histological/anatomical phenotyping\",\n      \"pmids\": [\"9409679\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct target genes mediating the phenotype not identified\", \"Cell-autonomy not resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Linked FOXC2 to human disease, establishing it as a dosage-sensitive transcription factor required for lymphatic development.\",\n      \"evidence\": \"Mutation sequencing in lymphedema-distichiasis families\",\n      \"pmids\": [\"11078474\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lymphatic target genes not yet defined\", \"Mechanism of dosage sensitivity unresolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Positioned FOXC2 downstream of BMP signaling in skeletal differentiation, answering how it contributes to osteogenesis.\",\n      \"evidence\": \"Antisense suppression in C2C12 with osteoblast marker readouts; BMP treatment and limb bud organ culture\",\n      \"pmids\": [\"10722840\", \"11585339\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct osteogenic target promoters not mapped\", \"Single lineage model\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Revealed FOXC2 as a metabolic regulator that reprograms \\u03b2-adrenergic/PKA signaling, explaining its lean/insulin-sensitive phenotype and identifying a direct promoter target.\",\n      \"evidence\": \"Transgenic overexpression with PKA holoenzyme biochemistry; PKA RI\\u03b1 1b promoter mapping and EMSA\",\n      \"pmids\": [\"11551504\", \"11943768\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the released repressor not defined\", \"Physiological signal controlling FOXC2 in adipose unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Established cooperative, dose-dependent FOXC1/FOXC2 control of paraxial mesoderm specification and somitogenesis, defining downstream transcriptional targets.\",\n      \"evidence\": \"Compound mouse mutants and chick gain-of-function with in situ readouts for paraxis, Mesp1/2, Hes5, Notch1, Pax7\",\n      \"pmids\": [\"11562355\", \"15196959\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect target regulation not distinguished\", \"Functional redundancy mechanism unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined how FOXC2 blocks adipogenesis, showing it inhibits PPAR\\u03b3-dependent gene expression without affecting PPAR\\u03b3 binding.\",\n      \"evidence\": \"Overexpression in 3T3-L1 with PPAR\\u03b3 transactivation and DNA-binding assays\",\n      \"pmids\": [\"15277530\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of selective PPAR\\u03b3 target inhibition unknown\", \"Direct DNA binding not shown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Connected FOXC2 to EMT and metastasis, establishing it as an effector induced by multiple EMT triggers and required for metastatic dissemination.\",\n      \"evidence\": \"Expression profiling, shRNA knockdown, overexpression, and in vivo lung metastasis assay\",\n      \"pmids\": [\"17537911\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct mesenchymal targets not yet identified\", \"Mechanism of metastatic enhancement unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified the first direct vascular and adhesion target genes (Ang-2, Itgb3) of FOXC2 with functional rescue, explaining its angiogenic activity.\",\n      \"evidence\": \"Transgenic models, promoter reporter/forkhead-element mapping, antagonist/neutralizing-antibody rescue, ex vivo aortic ring assay\",\n      \"pmids\": [\"18621714\", \"18579532\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full target repertoire not defined\", \"Upstream signals controlling these targets in vivo unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed FOXC2 directly represses p120-catenin and operates within a podocyte specification network, broadening its repressor function and developmental scope.\",\n      \"evidence\": \"Promoter deletion/EMSA with RNAi in lung cancer cells; morpholino and gain-of-function epistasis in Xenopus\",\n      \"pmids\": [\"20460685\", \"20431116\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of activation versus repression not defined\", \"Cofactors at repressed promoters unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined the FOXC2 lymphatic valve mechanism, linking it with PROX1, shear stress, connexin37, and calcineurin/NFAT signaling.\",\n      \"evidence\": \"Shear stress assays on LECs with PROX1/FOXC2 knockdown and mouse developmental genetics\",\n      \"pmids\": [\"22306086\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct FOXC2 targets in valve program incompletely mapped\", \"Mechanotransduction-to-FOXC2 link not molecular\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established post-translational control of FOXC2 chromatin recruitment by proline-directed phosphorylation, and de-SUMOylation by SENP3 as an activity switch.\",\n      \"evidence\": \"Genome-wide ChIP-seq with phospho-mutants and in vivo remodeling assay; SENP3 substrate biochemistry with N-cadherin reporter and xenograft\",\n      \"pmids\": [\"23878394\", \"25216525\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinases responsible for the eight sites not all identified\", \"How modifications direct site selection unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Placed FOXC2 within mTORC2-Akt and Wnt signaling axes and expanded its cancer stem cell and osteogenic roles via PDGFR-\\u03b2 and Wnt4.\",\n      \"evidence\": \"Gene-trap ESCs with BSTA-Akt1 co-IP; ChIP/reporter for Wnt4 and PDGFR-\\u03b2 with differentiation and CSC assays\",\n      \"pmids\": [\"23300339\", \"23645207\", \"23378344\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect PDGFR-\\u03b2 regulation not fully resolved\", \"Integration of signaling inputs unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Resolved subcellular localization control by CK2 phosphorylation at Ser124 and identified MET as a direct target, mechanistically connecting FOXC2 to invasion.\",\n      \"evidence\": \"In vitro kinase assay, co-IP, S124 mutagenesis, fractionation; ChIP/luciferase for MET with metastasis model and PKC\\u03b1-FOXC2-p120ctn axis\",\n      \"pmids\": [\"25486430\", \"25381815\", \"29216867\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphatase opposing CK2 not identified\", \"Crosstalk between CK2 and proline-directed phosphorylation unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined FOXC2 as a maintenance factor for lymphatic endothelial quiescence, acting through TAZ/Hippo and ERK to restrain proliferation and preserve junctions.\",\n      \"evidence\": \"Inducible endothelial Foxc2 deletion with TAZ pathway analysis and ERK activation/inhibition; Cx37 compound mutants\",\n      \"pmids\": [\"26389677\", \"27214551\", \"26079578\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct FOXC2 targets controlling TAZ/ERK not defined\", \"Quiescence versus differentiation roles not fully separated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Situated FOXC2 within upstream regulatory circuits in cancer (FOXF2 repression, p38MAPK induction), explaining context-dependent FOXC2 levels and EMT/therapy resistance.\",\n      \"evidence\": \"Promoter reporter and overexpression/knockdown with EMT/drug-resistance phenotyping; p38 inhibitor in vivo\",\n      \"pmids\": [\"26210254\", \"26804168\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect regulation by p38 unresolved\", \"Single tumor-type models\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Detailed cytoskeletal and cell-cycle control by FOXC2, including ROCK-dependent junction regulation and PLK1-dependent protein stability.\",\n      \"evidence\": \"siRNA/inducible deletion with ROCK inhibitor rescue and cytoskeletal imaging; cell-cycle-resolved protein quantification with PLK1 inhibition\",\n      \"pmids\": [\"32510325\", \"27064522\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of PLK1-dependent stabilization not defined\", \"Transcriptional targets driving cytoskeletal effects unmapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Provided molecular basis for lymphedema-distichiasis by showing disease mutations alter transactivation and can form lethal nuclear aggregates.\",\n      \"evidence\": \"Patient-derived mutation panels with reporter, localization, and viability assays\",\n      \"pmids\": [\"27276711\", \"32698337\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genotype-phenotype correlation incomplete\", \"Aggregate clearance pathway unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified FOXC2 protein-protein partnerships with YAP/TEAD and roles in metabolic reprogramming and adipose inflammation, expanding its interactome.\",\n      \"evidence\": \"Co-IP of FOXC2 with YAP/TEAD and glycolysis assays; STAT3-PRDM16 complex and leptin/JAK2-STAT3 axis with browning model\",\n      \"pmids\": [\"28433696\", \"28925407\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct DNA targets of FOXC2-YAP complex not mapped\", \"Single-lab interaction data\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Resolved the FOXC2 DNA-recognition mechanism at atomic resolution and connected its osteogenic Wnt4 program to lncRNA H19 binding.\",\n      \"evidence\": \"Two crystal structures of the DBD-DNA complex with biochemistry; RIP/pull-down and ChIP for H19/Foxc2/Wnt4 with Wnt-\\u03b2-catenin reporter\",\n      \"pmids\": [\"30722065\", \"24122419\", \"30633332\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for cofactor selectivity not addressed\", \"Functional role of H19-FOXC2 binding in vivo unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extended FOXC2 function to adult lymphatic homeostasis, gut barrier integrity, and LEC subtype identity using single-cell resolution.\",\n      \"evidence\": \"Inducible adult Foxc2 deletion with single-cell atlas and microbiota-depletion rescue\",\n      \"pmids\": [\"34272244\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct targets defining LEC subtype identity not identified\", \"Mechanism linking FOXC2 loss to barrier defect unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established RNA-mediated regulation of FOXC2 stability/localization and a coherent set of angiogenic promoter targets in tumor endothelium.\",\n      \"evidence\": \"circKIF18A-FOXC2 co-IP and ChIP on ITGB3/CXCR4/DLL4 promoters with PI3K/AKT readout and in vivo tumorigenicity\",\n      \"pmids\": [\"35637250\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of circRNA-mediated stabilization not detailed\", \"Single-lab data\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined cell-type-specific FOXC1/FOXC2 target loci (CXCL12, RSPO3) regulating intestinal stem cell Wnt signaling, and a FOXC2-driven vasculogenic mimicry program conferring anti-angiogenic resistance.\",\n      \"evidence\": \"EC/LEC-specific knockouts with ChIP on CXCL12/RSPO3 and ligand rescue; VM channel assays under hypoxia with anti-angiogenic combination in vivo\",\n      \"pmids\": [\"37154714\", \"37499655\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full endothelial target network not defined\", \"Determinants of FOXC1 versus FOXC2 target selectivity unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the combinatorial code of FOXC2 post-translational modifications and partner proteins selects context-specific target genes and the activation-versus-repression decision across its many tissue programs.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking phosphorylation/SUMOylation state to genome-wide site selection\", \"Cofactor determinants of activation versus repression not defined\", \"Tissue-specific target hierarchies incompletely mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 12, 13, 14, 22, 20, 36]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 14, 36]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [38, 41]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [23, 31, 21, 41]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 12, 13, 22, 14]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 6, 10, 16, 30]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [19, 33, 34, 37, 26]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 31, 39, 11, 22]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [5, 7, 9, 35, 34]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"FOXC1\", \"ERK\", \"CK2\", \"SENP3\", \"YAP\", \"TEAD\", \"PROX1\", \"Akt1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":9,"faith_total":9,"faith_pct":100.0}}